,sentence_text,e1,e2,relation_type,normalized_sentence
57,The findings suggest that the dosage of S-ketamine should be reduced in patients receiving ticlopidine.,S-ketamine,ticlopidine,advise,The_bf findings_bf suggest_bf dosage_bf DRUG reduced_be patients_be receiving_be OTHER_DRUG ._af
144,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ",tamoxifen,SSRI antidepressants,advise,"It_bf better_bf avoid_bf prescribing_bf isoenzyme_bf CYP_bf 2D6_bf inhibitors_bf women_bf treated_bf DRUG breast_be cancer_be ,_be especially_be SSRI_be antidepressants_be paroxetine_be fluoxetine_be ._be"
145,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ",tamoxifen,paroxetine,advise,"It_bf better_bf avoid_bf prescribing_bf isoenzyme_bf CYP_bf 2D6_bf inhibitors_bf women_bf treated_bf DRUG breast_be cancer_be ,_be especially_be SSRI_be antidepressants_be OTHER_DRUG fluoxetine_af ._af"
146,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ",tamoxifen,fluoxetine,advise,"It_bf better_bf avoid_bf prescribing_bf isoenzyme_bf CYP_bf 2D6_bf inhibitors_bf women_bf treated_bf DRUG breast_be cancer_be ,_be especially_be SSRI_be antidepressants_be paroxetine_be OTHER_DRUG ._af"
151,"If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.",antidepressant,tamoxifen,advise,"If_bf certain_bf cases_bf ,_bf DRUG considered_be necessary_be ,_be may_be advisable_be replace_be OTHER_DRUG anastrozole_af ._af"
213,Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. ,clopidogrel,omeprazole,advise,Regulatory_bf agencies_bf state_bf combination_bf DRUG CYP2C19_be inhibitors_be OTHER_DRUG esomeprazole_af avoided_af ._af
214,Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. ,clopidogrel,esomeprazole,advise,Regulatory_bf agencies_bf state_bf combination_bf DRUG CYP2C19_be inhibitors_be omeprazole_be OTHER_DRUG avoided_af ._af
418,Co-administration of ZETIA with fibrates is not recommended until use in patients is studied. ,ZETIA,fibrates,advise,Co-administration_bf DRUG OTHER_DRUG recommended_af use_af patients_af studied_af ._af
449,Patients who take both ezetimibe and cyclosporine should be carefully monitored. ,ezetimibe,cyclosporine,advise,Patients_bf take_bf DRUG OTHER_DRUG carefully_af monitored_af ._af
467,Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.  ,antibiotics,ganglion blockers,advise,Patients_bf receiving_bf DRUG sulfonamides_be generally_be treated_be ganglion_be blockers_be ._be
468,Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.  ,sulfonamides,ganglion blockers,advise,Patients_bf receiving_bf antibiotics_bf DRUG generally_be treated_be ganglion_be blockers_be ._be
481,Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate. ,indinavir,megestrol acetate,advise,Administration_bf higher_bf dose_bf DRUG considered_be coadministering_be megestrol_be acetate_be ._be
627,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. ,NSAIDs,ACE inhibitors,advise,This_bf interaction_bf given_bf consideration_bf patients_bf taking_bf DRUG concomitantly_be ACE_be inhibitors_be ._be
632,"however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. ",NSAIDs,aspirin,advise,"however_bf ,_bf DRUG ,_be concomitant_be administration_be meloxicam_be OTHER_DRUG generally_af recommended_af potential_af increased_af adverse_af effects_af ._af"
633,"however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. ",meloxicam,aspirin,advise,"however_bf ,_bf NSAIDs_bf ,_bf concomitant_bf administration_bf DRUG OTHER_DRUG generally_af recommended_af potential_af increased_af adverse_af effects_af ._af"
656,"Nevertheless, during concomitant therapy with furosemide and MOBIC, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy. ",furosemide,MOBIC,advise,"Nevertheless_bf ,_bf concomitant_bf therapy_bf DRUG OTHER_DRUG ,_af patients_af observed_af closely_af signs_af declining_af renal_af function_af ,_af well_af assure_af diuretic_af efficacy_af ._af"
669,Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn. ,lithium,MOBIC,advise,Patients_bf DRUG treatment_be closely_be monitored_be OTHER_DRUG introduced_af withdrawn_af ._af
677,"Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding. ",MOBIC,warfarin,advise,"Warfarin:_bf Anticoagulant_bf activity_bf monitored_bf ,_bf particularly_bf first_bf days_bf initiating_bf changing_bf DRUG therapy_be patients_be receiving_be OTHER_DRUG similar_af agents_af ,_af since_af patients_af increased_af risk_af bleeding_af ._af"
684,Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,MOBIC,warfarin,advise,Caution_bf used_bf administering_bf DRUG OTHER_DRUG since_af patients_af OTHER_DRUG may_af experience_af changes_af INR_af increased_af risk_af bleeding_af complications_af new_af medication_af introduced_af ._af
810,"Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.",aspirin,methazolamide,advise,"Caution_bf advised_bf patients_bf receiving_bf high-dose_bf DRUG OTHER_DRUG concomitantly_af ,_af anorexia_af ,_af tachypnea_af ,_af lethargy_af ,_af coma_af death_af reported_af concomitant_af use_af high-dose_af DRUG carbonic_af anhydrase_af inhibitors_af ._af"
830,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",levomepromazine,anticholinergic drugs,advise,"Exert_bf particular_bf caution_bf combining_bf DRUG anticholinergic_be drugs_be (tricyclic_be antidepressants_be antiparkinsonian-agents):_be Particularly_be elderly_be may_be develop_be delirium_be ,_be high_be fever_be ,_be severe_be obstipation_be ,_be even_be ileus_be glaucoma_be ._be"
831,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",levomepromazine,tricyclic antidepressants,advise,"Exert_bf particular_bf caution_bf combining_bf DRUG anticholinergic_be drugs_be (tricyclic_be antidepressants_be antiparkinsonian-agents):_be Particularly_be elderly_be may_be develop_be delirium_be ,_be high_be fever_be ,_be severe_be obstipation_be ,_be even_be ileus_be glaucoma_be ._be"
832,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",levomepromazine,antiparkinsonian-agents,advise,"Exert_bf particular_bf caution_bf combining_bf DRUG anticholinergic_be drugs_be (tricyclic_be antidepressants_be antiparkinsonian-agents):_be Particularly_be elderly_be may_be develop_be delirium_be ,_be high_be fever_be ,_be severe_be obstipation_be ,_be even_be ileus_be glaucoma_be ._be"
843,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",Celontin,antiepileptic drugs,advise,"Since_bf DRUG (methsuximide)_be may_be interact_be concurrently_be administered_be antiepileptic_be drugs_be ,_be periodic_be serum_be level_be determinations_be drugs_be may_be necessary_be (eg_be methsuximide_be may_be increase_be plasma_be concentrations_be phenytoin_be phenobarbital)_be ._be"
847,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",methsuximide,antiepileptic drugs,advise,"Since_bf Celontin_bf (methsuximide)_bf may_bf interact_bf concurrently_bf administered_bf antiepileptic_bf drugs_bf ,_bf periodic_bf serum_bf level_bf determinations_bf drugs_bf may_bf necessary_bf (eg_bf DRUG may_be increase_be plasma_be concentrations_be phenytoin_be phenobarbital)_be ._be"
866,Patients may require reduced doses of anesthetics when on methyldopa. ,anesthetics,methyldopa,advise,Patients_bf may_bf require_bf reduced_bf doses_bf DRUG OTHER_DRUG ._af
867,When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. ,methyldopa,lithium,advise,When_bf DRUG OTHER_DRUG given_af concomitantly_af patient_af carefully_af monitored_af symptoms_af OTHER_DRUG toxicity_af ._af
873,Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. ,methyldopa,ferrous sulfate,advise,Coadministration_bf DRUG ferrous_be sulfate_be ferrous_be gluconate_be recommended_be ._be
874,Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. ,methyldopa,ferrous gluconate,advise,Coadministration_bf DRUG ferrous_be sulfate_be ferrous_be gluconate_be recommended_be ._be
1009,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,Methergine,vasoconstrictors,advise,Caution_bf exercised_bf DRUG (methylergonovine_be maleate)_be used_be concurrently_be OTHER_DRUG ergot_af alkaloids_af ._af
1010,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,Methergine,ergot alkaloids,advise,Caution_bf exercised_bf DRUG (methylergonovine_be maleate)_be used_be concurrently_be vasoconstrictors_be ergot_be alkaloids_be ._be
1011,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,methylergonovine maleate,vasoconstrictors,advise,Caution_bf exercised_bf Methergine_bf (methylergonovine_bf maleate)_bf used_bf concurrently_bf OTHER_DRUG ergot_be alkaloids_be ._be
1078,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenobarbital,methylprednisolone,advise,"Drugs_bf induce_bf hepatic_bf enzymes_bf DRUG ,_be phenytoin_be ,_be rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increased_af OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
1081,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenytoin,methylprednisolone,advise,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf DRUG ,_be rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increased_af OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
1083,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",rifampin,methylprednisolone,advise,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf phenytoin_bf ,_bf DRUG may_be increase_be clearance_be OTHER_DRUG may_af require_af increased_af OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
1092,Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. ,Aspirin,corticosteroids,advise,DRUG used_be cautiously_be conjunction_be OTHER_DRUG patients_af suffering_af hypoprothrombinemia_af ._af
1376,"The finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxi-dase inhibitors. ",metoclopramide,monoamine oxi-dase inhibitors,advise,"The_bf finding_bf DRUG releases_be catecholamines_be patients_be essential_be hypertension_be suggests_be used_be cautiously_be ,_be ,_be patients_be receiving_be monoamine_be oxi-dase_be inhibitors_be ._be"
1398,"Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment.",metoclopramide,insulin,advise,"Because_bf action_bf DRUG influence_be delivery_be food_be intestines_be thus_be rate_be absorption_be ,_be OTHER_DRUG dosage_af timing_af dosage_af may_af require_af adjustment_af ._af"
1409,Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,DEMSER,phenothiazines,advise,Caution_bf observed_bf administering_bf DRUG patients_be receiving_be OTHER_DRUG haloperidol_af extrapyramidal_af effects_af drugs_af expected_af potentiated_af inhibition_af catecholamine_af synthesis_af ._af
1410,Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,DEMSER,haloperidol,advise,Caution_bf observed_bf administering_bf DRUG patients_be receiving_be phenothiazines_be OTHER_DRUG extrapyramidal_af effects_af drugs_af expected_af potentiated_af inhibition_af catecholamine_af synthesis_af ._af
1484,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,theophylline,advise,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf DRUG ._be OTHER_DRUG plasma_af levels_af returned_af pre-Mexitil_af values_af within_af 48_af hours_af discontinuing_af DRUG ._af If_af DRUG OTHER_DRUG used_af concurrently_af ,_af OTHER_DRUG blood_af levels_af monitored_af ,_af particularly_af DRUG dose_af changed_af ._af"
1573,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,sirolimus,MYCAMINE,advise,Patients_bf receiving_bf DRUG nifedipine_be combination_be OTHER_DRUG monitored_af DRUG nifedipine_af toxicity_af DRUG nifedipine_af dosage_af reduced_af necessary_af ._af
1578,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,nifedipine,MYCAMINE,advise,Patients_bf receiving_bf sirolimus_bf DRUG combination_be OTHER_DRUG monitored_af sirolimus_af DRUG toxicity_af sirolimus_af DRUG dosage_af reduced_af necessary_af ._af
1593,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",midazolam,azole antimycotics,advise,"Drug_bf Interactions:_bf Inhibitors_bf CYP3A4_bf Isozymes:_bf Caution_bf advised_bf DRUG administered_be concomitantly_be drugs_be known_be inhibit_be cytochrome_be P450_be 3A4_be enzyme_be system_be (ie_be ,_be drugs_be drug_be classes_be azole_be antimycotics_be ,_be protease_be inhibitors_be ,_be calcium_be channel_be antagonists_be ,_be macrolide_be antibiotics)_be ._be"
1594,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",midazolam,protease inhibitors,advise,"Drug_bf Interactions:_bf Inhibitors_bf CYP3A4_bf Isozymes:_bf Caution_bf advised_bf DRUG administered_be concomitantly_be drugs_be known_be inhibit_be cytochrome_be P450_be 3A4_be enzyme_be system_be (ie_be ,_be drugs_be drug_be classes_be azole_be antimycotics_be ,_be protease_be inhibitors_be ,_be calcium_be channel_be antagonists_be ,_be macrolide_be antibiotics)_be ._be"
1595,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",midazolam,calcium channel antagonists,advise,"Drug_bf Interactions:_bf Inhibitors_bf CYP3A4_bf Isozymes:_bf Caution_bf advised_bf DRUG administered_be concomitantly_be drugs_be known_be inhibit_be cytochrome_be P450_be 3A4_be enzyme_be system_be (ie_be ,_be drugs_be drug_be classes_be azole_be antimycotics_be ,_be protease_be inhibitors_be ,_be calcium_be channel_be antagonists_be ,_be macrolide_be antibiotics)_be ._be"
1596,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",midazolam,macrolide antibiotics,advise,"Drug_bf Interactions:_bf Inhibitors_bf CYP3A4_bf Isozymes:_bf Caution_bf advised_bf DRUG administered_be concomitantly_be drugs_be known_be inhibit_be cytochrome_be P450_be 3A4_be enzyme_be system_be (ie_be ,_be drugs_be drug_be classes_be azole_be antimycotics_be ,_be protease_be inhibitors_be ,_be calcium_be channel_be antagonists_be ,_be macrolide_be antibiotics)_be ._be"
1844,Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.,Cerezyme,ZAVESCA,advise,Combination_bf therapy_bf DRUG (imiglucerase)_be OTHER_DRUG indicated_af ._af
1845,Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.,imiglucerase,ZAVESCA,advise,Combination_bf therapy_bf Cerezyme_bf (imiglucerase)_bf OTHER_DRUG indicated_be ._be
1846,"Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ",tetracyclines,anticoagulant,advise,"Because_bf DRUG shown_be depress_be plasma_be prothrombin_be activity_be ,_be patients_be OTHER_DRUG therapy_af may_af require_af downward_af adjustment_af OTHER_DRUG dosage_af ._af"
1851,"Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin. ",tetracycline class drugs,penicillin,advise,"Since_bf bacteriostatic_bf drugs_bf may_bf interfere_bf bactericidal_bf action_bf OTHER_DRUG ,_be advisable_be avoid_be giving_be tetracycline_be class_be drugs_be conjunction_be OTHER_DRUG ._af"
1874,If at all possible guanethidine should be discontinued well before minoxidil is begun. ,guanethidine,minoxidil,advise,If_bf possible_bf DRUG discontinued_be well_be OTHER_DRUG begun_af ._af
1883,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",alcohol,REMERON SolTab,advise,"Accordingly_bf ,_bf patients_bf advised_bf avoid_bf DRUG taking_be REMERON_be SolTab_be ._be Diazepam:_be Concomitant_be administration_be diazepam_be (15_be mg)_be minimal_be effect_be plasma_be levels_be mirtazapine_be (15_be mg)_be 12_be healthy_be subjects_be ._be"
1894,"Accordingly, patients should be advised to avoid diazepam and other similar drugs while taking REMERON SolTab.",diazepam,REMERON SolTab,advise,"Accordingly_bf ,_bf patients_bf advised_bf avoid_bf DRUG similar_be drugs_be taking_be REMERON_be SolTab_be ._be"
1900,"Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants. ",Mitotane,coumarin-type anticoagulants,advise,"Therefore_bf ,_bf physicians_bf closely_bf monitor_bf patients_bf change_bf anticoagulant_bf dosage_bf requirements_bf administering_bf DRUG patients_be coumarin-type_be anticoagulants_be ._be"
1905,Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON. ,succinylcholine,MIVACRON,advise,Evidence_bf spontaneous_bf recovery_bf DRUG observed_be administration_be OTHER_DRUG ._af
2233,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. ",phenobarbital,montelukast,advise,"It_bf reasonable_bf employ_bf appropriate_bf clinical_bf monitoring_bf potent_bf cytochrome_bf P450_bf enzyme_bf inducers_bf ,_bf DRUG rifampin_be ,_be co-administered_be OTHER_DRUG ._af"
2234,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. ",rifampin,montelukast,advise,"It_bf reasonable_bf employ_bf appropriate_bf clinical_bf monitoring_bf potent_bf cytochrome_bf P450_bf enzyme_bf inducers_bf ,_bf phenobarbital_bf DRUG ,_be co-administered_be OTHER_DRUG ._af"
2294,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.",phenobarbital,montelukast,advise,"It_bf reasonable_bf employ_bf appropriate_bf clinical_bf monitoring_bf potent_bf cytochrome_bf P450_bf enzyme_bf inducers_bf ,_bf DRUG rifampin_be ,_be co-administered_be OTHER_DRUG ._af"
2295,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.",rifampin,montelukast,advise,"It_bf reasonable_bf employ_bf appropriate_bf clinical_bf monitoring_bf potent_bf cytochrome_bf P450_bf enzyme_bf inducers_bf ,_bf phenobarbital_bf DRUG ,_be co-administered_be OTHER_DRUG ._af"
2328,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",Agonist/antagonist analgesics,opioid agonist analgesic,advise,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf butorphanol_bf ,_bf buprenorphine)_bf NOT_bf administered_bf patients_bf received_bf receiving_bf course_bf therapy_bf proof_bf opioid_bf agonist_bf analgesic_bf ._bf"
2332,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",pentazocine,opioid agonist analgesic,advise,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf DRUG ,_be nalbuphine_be ,_be butorphanol_be ,_be buprenorphine)_be NOT_be administered_be patients_be received_be receiving_be course_be therapy_be proof_be opioid_be agonist_be analgesic_be ._be"
2335,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",nalbuphine,opioid agonist analgesic,advise,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf DRUG ,_be butorphanol_be ,_be buprenorphine)_be NOT_be administered_be patients_be received_be receiving_be course_be therapy_be proof_be opioid_be agonist_be analgesic_be ._be"
2337,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",butorphanol,opioid agonist analgesic,advise,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf DRUG ,_be buprenorphine)_be NOT_be administered_be patients_be received_be receiving_be course_be therapy_be proof_be opioid_be agonist_be analgesic_be ._be"
2338,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",buprenorphine,opioid agonist analgesic,advise,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf butorphanol_bf ,_bf buprenorphine)_bf NOT_bf administered_bf patients_bf received_bf receiving_bf course_bf therapy_bf proof_bf opioid_bf agonist_bf analgesic_bf ._bf"
2354,It is recommended that Myfortic and antacids not be administered simultaneously. ,Myfortic,antacids,advise,It_bf recommended_bf DRUG OTHER_DRUG administered_af simultaneously_af ._af
2382,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",Myfortic,azathioprine,advise,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf OTHER_DRUG mycophenolate_be mofetil_be inhibit_be purine_be metabolism_be ,_be recommended_be DRUG administered_af concomitantly_af OTHER_DRUG mycophenolate_af mofetil_af ._af"
2383,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",Myfortic,mycophenolate mofetil,advise,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf azathioprine_bf mycophenolate_bf mofetil_bf inhibit_bf purine_bf metabolism_bf ,_bf recommended_bf DRUG administered_be concomitantly_be azathioprine_be mycophenolate_be mofetil_be ._be"
2388,"Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ",Myfortic,cholestyramine,advise,"Therefore_bf ,_bf administer_bf DRUG OTHER_DRUG agents_af may_af interfere_af enterohepatic_af recirculation_af drugs_af may_af bind_af bile_af acids_af ,_af example_af bile_af acid_af sequestrates_af oral_af activated_af charcoal_af ,_af potential_af reduce_af efficacy_af DRUG ._af"
2389,"Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ",Myfortic,activated charcoal,advise,"Therefore_bf ,_bf administer_bf DRUG cholestyramine_be agents_be may_be interfere_be enterohepatic_be recirculation_be drugs_be may_be bind_be bile_be acids_be ,_be example_be bile_be acid_be sequestrates_be oral_be activated_be charcoal_be ,_be potential_be reduce_be efficacy_be DRUG ._af"
2398,"Therefore, it is recommended that oral contraceptives are co- administered with Myfortic with caution and additional birth control methods be considered. ",contraceptives,Myfortic,advise,"Therefore_bf ,_bf recommended_bf oral_bf DRUG co-_be administered_be OTHER_DRUG caution_af additional_af birth_af control_af methods_af considered_af ._af"
2401,"Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective. ",Myfortic,live attenuated vaccines,advise,"Live_bf Vaccines:_bf During_bf treatment_bf DRUG ,_be use_be live_be attenuated_be vaccines_be avoided_be patients_be advised_be vaccinations_be may_be less_be effective_be ._be"
2460,Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects. ,beta adrenergic aerosol bronchodilators,Alupent,advise,Other_bf beta_bf adrenergic_bf aerosol_bf bronchodilators_bf used_bf concomitantly_bf OTHER_DRUG (metaproterenol_be sulfate_be USP)_be may_be additive_be effects_be ._be
2461,Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects. ,beta adrenergic aerosol bronchodilators,metaproterenol sulfate,advise,Other_bf beta_bf adrenergic_bf aerosol_bf bronchodilators_bf used_bf concomitantly_bf Alupent_bf (metaproterenol_bf sulfate_bf USP)_bf may_bf additive_bf effects_bf ._bf
2463,"Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.",Beta adrenergic agonists,monoamine oxidase inhibitors,advise,"Beta_bf adrenergic_bf agonists_bf administered_bf caution_bf patients_bf treated_bf monoamine_bf oxidase_bf inhibitors_bf tricyclic_bf antidepressants_bf ,_bf since_bf action_bf beta_bf adrenergic_bf agonists_bf vascular_bf system_bf may_bf potentiated_bf ._bf"
2464,"Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.",Beta adrenergic agonists,tricyclic antidepressants,advise,"Beta_bf adrenergic_bf agonists_bf administered_bf caution_bf patients_bf treated_bf monoamine_bf oxidase_bf inhibitors_bf tricyclic_bf antidepressants_bf ,_bf since_bf action_bf beta_bf adrenergic_bf agonists_bf vascular_bf system_bf may_bf potentiated_bf ._bf"
2551,"Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",warfarin,XENICAL,advise,"Therefore_bf ,_bf vitamin_bf K_bf absorption_bf may_bf decreased_bf OTHER_DRUG ,_be patients_be chronic_be stable_be doses_be DRUG prescribed_af OTHER_DRUG monitored_af closely_af changes_af coagulation_af parameters_af ._af"
2571,"When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved. ",oxandrolone,warfarin,advise,"When_bf DRUG therapy_be initiated_be patient_be already_be receiving_be treatment_be OTHER_DRUG ,_af INR_af prothrombin_af time_af (PT)_af monitored_af closely_af dose_af OTHER_DRUG adjusted_af necessary_af stable_af target_af INR_af PT_af achieved_af ._af"
2574,"Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the warfarin dosage if indicated are recommended when the oxandrolone dose is changed or discontinued. ",warfarin,oxandrolone,advise,"Furthermore_bf ,_bf patients_bf receiving_bf drugs_bf ,_bf careful_bf monitoring_bf INR_bf PT_bf ,_bf adjustment_bf DRUG dosage_be indicated_be recommended_be OTHER_DRUG dose_af changed_af discontinued_af ._af"
2681,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",paliperidone,centrally acting drugs,advise,"Given_bf primary_bf CNS_bf effects_bf DRUG ,_be INVEGA_be used_be caution_be combination_be centrally_be acting_be drugs_be alcohol_be ._be"
2682,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",paliperidone,alcohol,advise,"Given_bf primary_bf CNS_bf effects_bf DRUG ,_be INVEGA_be used_be caution_be combination_be centrally_be acting_be drugs_be OTHER_DRUG ._af"
2683,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",INVEGA,centrally acting drugs,advise,"Given_bf primary_bf CNS_bf effects_bf paliperidone_bf ,_bf DRUG used_be caution_be combination_be centrally_be acting_be drugs_be alcohol_be ._be"
2684,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",INVEGA,alcohol,advise,"Given_bf primary_bf CNS_bf effects_bf paliperidone_bf ,_bf DRUG used_be caution_be combination_be centrally_be acting_be drugs_be OTHER_DRUG ._af"
2994,Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time. ,proton pump inhibitors,warfarin,advise,Patients_bf treated_bf proton_bf pump_bf inhibitors_bf OTHER_DRUG concomitantly_be monitored_be increases_be INR_be prothrombin_be time_be ._be
3061,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,ketoconazole,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf OTHER_DRUG approximately_be doubled_be DRUG AUC0-_af ._af Since_af DRUG partially_af metabolized_af CYP3A_af OTHER_DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG OTHER_DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3062,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,atazanavir,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af OTHER_DRUG ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3063,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,clarithromycin,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af OTHER_DRUG ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3064,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,indinavir,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af OTHER_DRUG ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3065,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,itraconazole,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af OTHER_DRUG ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3066,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,nefazodone,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af OTHER_DRUG ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3067,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,nelfinavir,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af OTHER_DRUG ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3068,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,ritonavir,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af OTHER_DRUG ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3069,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,saquinavir,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af OTHER_DRUG ,_af telithromycin_af voriconazole_af ._af"
3070,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,telithromycin,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af OTHER_DRUG voriconazole_af ._af"
3071,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,voriconazole,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af OTHER_DRUG ._af"
3127,"Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole. ",Zemplar,ketoconazole,advise,"Dose_bf adjustment_bf DRUG Capsules_be may_be required_be ,_be iPTH_be serum_be calcium_be concentrations_be closely_be monitored_be patient_be initiates_be discontinues_be therapy_be strong_be CYP3A4_be inhibitor_be OTHER_DRUG ._af"
3131,patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.,lithium,Neulasta,advise,patients_bf receiving_bf DRUG OTHER_DRUG frequent_af monitoring_af neutrophil_af counts_af ._af
3133,Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. ,insulin,SOMAVERT,advise,Acromegalic_bf patients_bf diabetes_bf mellitus_bf treated_bf DRUG and/or_be oral_be hypoglycemic_be agents_be may_be require_be dose_be reductions_be therapeutic_be agents_be initiation_be therapy_be OTHER_DRUG ._af
3134,Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. ,hypoglycemic,SOMAVERT,advise,Acromegalic_bf patients_bf diabetes_bf mellitus_bf treated_bf insulin_bf and/or_bf oral_bf DRUG agents_be may_be require_be dose_be reductions_be therapeutic_be agents_be initiation_be therapy_be OTHER_DRUG ._af
3142,"Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.",alcohol,pentazocine,advise,"Usage_bf Alcohol:_bf Due_bf potential_bf increased_bf CNS_bf depressants_bf effects_bf ,_bf DRUG used_be caution_be patients_be currently_be receiving_be OTHER_DRUG ._af"
3178,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",Dopamine antagonists,Permax,advise,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthines_bf )_bf metoclopramide_bf ,_bf ordinarily_bf administered_bf concurrently_bf OTHER_DRUG (a_be dopamine_be agonist);_be"
3184,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",neuroleptics,Permax,advise,"Dopamine_bf antagonists_bf ,_bf DRUG (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthines_be )_be metoclopramide_be ,_be ordinarily_be administered_be concurrently_be OTHER_DRUG (a_af dopamine_af agonist);_af"
3189,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",phenothiazines,Permax,advise,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthines_bf )_bf metoclopramide_bf ,_bf ordinarily_bf administered_bf concurrently_bf OTHER_DRUG (a_be dopamine_be agonist);_be"
3193,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",butyrophenones,Permax,advise,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf DRUG ,_be thioxanthines_be )_be metoclopramide_be ,_be ordinarily_be administered_be concurrently_be OTHER_DRUG (a_af dopamine_af agonist);_af"
3196,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",thioxanthines,Permax,advise,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf DRUG )_be metoclopramide_be ,_be ordinarily_be administered_be concurrently_be OTHER_DRUG (a_af dopamine_af agonist);_af"
3198,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",metoclopramide,Permax,advise,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthines_bf )_bf DRUG ,_be ordinarily_be administered_be concurrently_be OTHER_DRUG (a_af dopamine_af agonist);_af"
3206,"If diuretics cannot be interrupted, close medical supervision should be provided with the first dose of ACEON    Tablets, for at least two hours and until blood pressure has stabilized for another hour. ",diuretics,ACEON,advise,"If_bf DRUG cannot_be interrupted_be ,_be close_be medical_be supervision_be provided_be first_be dose_be OTHER_DRUG Tablets_af ,_af least_af two_af hours_af blood_af pressure_af stabilized_af another_af hour_af ._af"
3288,Pilocarpine should be administered with caution to patients taking beta adrenergic antagonists because of the possibility of conduction disturbances. ,Pilocarpine,beta adrenergic antagonists,advise,DRUG administered_be caution_be patients_be taking_be beta_be adrenergic_be antagonists_be possibility_be conduction_be disturbances_be ._be
3380,Other short-acting beta adrenergic aerosol bronchodilators should not be used concomitantly with MAXAIR AUTOHALER because they may have additive effects.,short-acting beta adrenergic aerosol bronchodilators,MAXAIR AUTOHALER,advise,Other_bf short-acting_bf beta_bf adrenergic_bf aerosol_bf bronchodilators_bf used_bf concomitantly_bf MAXAIR_bf AUTOHALER_bf may_bf additive_bf effects_bf ._bf
3390,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",FELDENE,coumarin-type anticoagulants,advise,"Although_bf occurred_bf vitro_bf studies_bf coumarin-type_bf anticoagulants_bf ,_bf interactions_bf coumarin-type_bf anticoagulants_bf reported_bf DRUG since_be marketing_be ,_be therefore_be ,_be physicians_be closely_be monitor_be patients_be change_be dosage_be requirements_be administering_be DRUG patients_af coumarin-type_af anticoagulants_af highly_af protein-bound_af drugs_af ._af"
3419,"It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.",lithium,FELDENE,advise,"It_bf recommended_bf plasma_bf DRUG levels_be monitored_be initiating_be ,_be adjusting_be discontinuing_be OTHER_DRUG ._af"
3618,Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. ,Aspirin,corticosteroids,advise,DRUG used_be cautiously_be conjunction_be OTHER_DRUG patients_af suffering_af hypoprothrombinemia_af ._af
3649,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",DIPRIVAN,analgesic agents,advise,"During_bf maintenance_bf anesthesia_bf sedation_bf ,_bf rate_bf DRUG Injectable_be Emulsion_be administration_be adjusted_be according_be desired_be level_be anesthesia_be sedation_be may_be reduced_be presence_be supplemental_be analgesic_be agents_be (eg_be ,_be nitrous_be oxide_be opioids)_be ._be"
3650,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",DIPRIVAN,nitrous oxide,advise,"During_bf maintenance_bf anesthesia_bf sedation_bf ,_bf rate_bf DRUG Injectable_be Emulsion_be administration_be adjusted_be according_be desired_be level_be anesthesia_be sedation_be may_be reduced_be presence_be supplemental_be analgesic_be agents_be (eg_be ,_be nitrous_be oxide_be opioids)_be ._be"
3651,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",DIPRIVAN,opioids,advise,"During_bf maintenance_bf anesthesia_bf sedation_bf ,_bf rate_bf DRUG Injectable_be Emulsion_be administration_be adjusted_be according_be desired_be level_be anesthesia_be sedation_be may_be reduced_be presence_be supplemental_be analgesic_be agents_be (eg_be ,_be nitrous_be oxide_be opioids)_be ._be"
3708,Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ,Cholestyramine,EVISTA,advise,Cholestyramine:_bf DRUG causes_be 60%_be reduction_be absorption_be enterohepatic_be cycling_be raloxifene_be coadministered_be OTHER_DRUG ._af
3713,"If EVISTA is given concurrently with warfarin, prothrombin time should be monitored. ",EVISTA,warfarin,advise,"If_bf DRUG given_be concurrently_be OTHER_DRUG ,_af prothrombin_af time_af monitored_af ._af"
3720,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,clofibrate,advise,"Caution_bf used_bf DRUG coadministered_be highly_be protein-bound_be drugs_be ,_be OTHER_DRUG ,_af indomethacin_af ,_af naproxen_af ,_af ibuprofen_af ,_af diazepam_af ,_af diazoxide_af ._af"
3721,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,indomethacin,advise,"Caution_bf used_bf DRUG coadministered_be highly_be protein-bound_be drugs_be ,_be clofibrate_be ,_be OTHER_DRUG ,_af naproxen_af ,_af ibuprofen_af ,_af diazepam_af ,_af diazoxide_af ._af"
3722,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,naproxen,advise,"Caution_bf used_bf DRUG coadministered_be highly_be protein-bound_be drugs_be ,_be clofibrate_be ,_be indomethacin_be ,_be OTHER_DRUG ,_af ibuprofen_af ,_af diazepam_af ,_af diazoxide_af ._af"
3723,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,ibuprofen,advise,"Caution_bf used_bf DRUG coadministered_be highly_be protein-bound_be drugs_be ,_be clofibrate_be ,_be indomethacin_be ,_be naproxen_be ,_be OTHER_DRUG ,_af diazepam_af ,_af diazoxide_af ._af"
3724,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,diazepam,advise,"Caution_bf used_bf DRUG coadministered_be highly_be protein-bound_be drugs_be ,_be clofibrate_be ,_be indomethacin_be ,_be naproxen_be ,_be ibuprofen_be ,_be OTHER_DRUG ,_af diazoxide_af ._af"
3725,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,diazoxide,advise,"Caution_bf used_bf DRUG coadministered_be highly_be protein-bound_be drugs_be ,_be clofibrate_be ,_be indomethacin_be ,_be naproxen_be ,_be ibuprofen_be ,_be diazepam_be ,_be OTHER_DRUG ._af"
3866,"If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. ",ZEMURON,succinylcholine,advise,"If_bf DRUG administered_be following_be administration_be OTHER_DRUG ,_af given_af recovery_af OTHER_DRUG observed_af ._af"
3871,"Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive. ",Ropivacaine,anesthetics,advise,"DRUG used_be caution_be patients_be receiving_be local_be OTHER_DRUG agents_af structurally_af related_af amide-type_af local_af OTHER_DRUG ,_af since_af toxic_af effects_af drugs_af additive_af ._af"
3907,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ",roxithromycin,terfenadine,advise,"Although_bf reaction_bf demonstrated_bf DRUG ,_be concomitant_be administration_be DRUG OTHER_DRUG astemizole_af recommended_af ._af"
3908,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ",roxithromycin,astemizole,advise,"Although_bf reaction_bf demonstrated_bf DRUG ,_be concomitant_be administration_be DRUG terfenadine_af OTHER_DRUG recommended_af ._af"
3996,Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors. ,VESIcare,ketoconazole,advise,Do_bf exceed_bf 5_bf mg_bf daily_bf dose_bf DRUG administered_be therapeutic_be doses_be OTHER_DRUG potent_af CYP3A4_af inhibitors_af ._af
4015,Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. irinotecan). ,NEXAVAR,irinotecan,advise,Caution_bf recommended_bf administering_bf DRUG compounds_be metabolized/eliminated_be predominantly_be UGT1A1_be pathway_be (e_be ._be g_be ._be irinotecan)_be ._be
4017,Caution is recommended when administering doxorubicin with NEXAVAR. ,doxorubicin,NEXAVAR,advise,Caution_bf recommended_bf administering_bf DRUG OTHER_DRUG ._af
4019,"Therefore, use of zidovudine in combination with ZERIT should be avoided. ",zidovudine,ZERIT,advise,"Therefore_bf ,_bf use_bf DRUG combination_be OTHER_DRUG avoided_af ._af"
4043,a reduction of the doxorubicin dosage should be considered in patients receiving ZANOSAR concurrently. ,doxorubicin,ZANOSAR,advise,reduction_bf DRUG dosage_be considered_be patients_be receiving_be OTHER_DRUG concurrently_af ._af
4048,"Concomitant administration of CHEMET with other chelation therapy, such as CaNa 2 EDTA is not recommended. ",CHEMET,CaNa 2 EDTA,advise,"Concomitant_bf administration_bf DRUG chelation_be therapy_be ,_be CaNa_be 2_be EDTA_be recommended_be ._be"
4127,"However, interactions may be expected and FLOMAX capsules should NOT be used in combination with other alpha-adrenergic blocking agents. ",FLOMAX,alpha-adrenergic blocking agents,advise,"However_bf ,_bf interactions_bf may_bf expected_bf DRUG capsules_be NOT_be used_be combination_be alpha-adrenergic_be blocking_be agents_be ._be"
4129,"Therefore, FLOMAX capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. ",FLOMAX,cimetidine,advise,"Therefore_bf ,_bf DRUG capsules_be used_be caution_be combination_be OTHER_DRUG ,_af particularly_af doses_af higher_af 0_af ._af 4_af mg_af ._af"
4131,"Therefore, caution should be exercised with concomitant administration of warfarin and FLOMAX capsules.        ",warfarin,FLOMAX,advise,"Therefore_bf ,_bf caution_bf exercised_bf concomitant_bf administration_bf DRUG OTHER_DRUG capsules_af ._af"
4215,Concomitant administration of ketoconazole and terfenadine is contraindicated. ,ketoconazole,terfenadine,advise,Concomitant_bf administration_bf DRUG OTHER_DRUG contraindicated_af ._af
4226,Concomitant administration of itraconazole and terfenadine is contraindicated. ,itraconazole,terfenadine,advise,Concomitant_bf administration_bf DRUG OTHER_DRUG contraindicated_af ._af
4232,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",azole-type antifungal agents,terfenadine,advise,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf fluconazole_bf ,_bf metronidazole_bf ,_bf miconazole)_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf concomitant_bf use_bf products_bf OTHER_DRUG recommended_be pending_be full_be examination_be potential_be interactions_be ._be"
4237,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",fluconazole,terfenadine,advise,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf DRUG ,_be metronidazole_be ,_be miconazole)_be ketoconazole_be ,_be itraconazole_be ,_be concomitant_be use_be products_be OTHER_DRUG recommended_af pending_af full_af examination_af potential_af interactions_af ._af"
4241,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",metronidazole,terfenadine,advise,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf fluconazole_bf ,_bf DRUG ,_be miconazole)_be ketoconazole_be ,_be itraconazole_be ,_be concomitant_be use_be products_be OTHER_DRUG recommended_af pending_af full_af examination_af potential_af interactions_af ._af"
4244,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",miconazole,terfenadine,advise,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf fluconazole_bf ,_bf metronidazole_bf ,_bf miconazole)_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf concomitant_bf use_bf products_bf OTHER_DRUG recommended_be pending_be full_be examination_be potential_be interactions_be ._be"
4259,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,clarithromycin,advise,"Concomitant_bf administration_bf DRUG OTHER_DRUG ,_af erythromycin_af ,_af troleandomycin_af contraindicated:_af Pending_af full_af characterization_af potential_af interactions_af ,_af concomitant_af administration_af DRUG macrolide_af antibiotics_af ,_af including_af azithromycin_af ,_af recommended_af ._af"
4260,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,erythromycin,advise,"Concomitant_bf administration_bf DRUG clarithromycin_be ,_be OTHER_DRUG ,_af troleandomycin_af contraindicated:_af Pending_af full_af characterization_af potential_af interactions_af ,_af concomitant_af administration_af DRUG macrolide_af antibiotics_af ,_af including_af azithromycin_af ,_af recommended_af ._af"
4261,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,troleandomycin,advise,"Concomitant_bf administration_bf DRUG clarithromycin_be ,_be erythromycin_be ,_be OTHER_DRUG contraindicated:_af Pending_af full_af characterization_af potential_af interactions_af ,_af concomitant_af administration_af DRUG macrolide_af antibiotics_af ,_af including_af azithromycin_af ,_af recommended_af ._af"
4277,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,macrolide antibiotics,advise,"Concomitant_bf administration_bf DRUG clarithromycin_be ,_be erythromycin_be ,_be troleandomycin_be contraindicated:_be Pending_be full_be characterization_be potential_be interactions_be ,_be concomitant_be administration_be DRUG macrolide_af antibiotics_af ,_af including_af azithromycin_af ,_af recommended_af ._af"
4278,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,azithromycin,advise,"Concomitant_bf administration_bf DRUG clarithromycin_be ,_be erythromycin_be ,_be troleandomycin_be contraindicated:_be Pending_be full_be characterization_be potential_be interactions_be ,_be concomitant_be administration_be DRUG macrolide_af antibiotics_af ,_af including_af OTHER_DRUG ,_af recommended_af ._af"
4349,"Therefore, when concomitant use of thiabendazole and xanthine derivatives is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds. ",thiabendazole,xanthine derivatives,advise,"Therefore_bf ,_bf concomitant_bf use_bf DRUG xanthine_be derivatives_be anticipated_be ,_be may_be necessary_be monitor_be blood_be levels_be and/or_be reduce_be dosage_be compounds_be ._be"
4397,Caution should be exercised when administering ZADAXIN therapy in combination with other immunomodulating drugs. ,ZADAXIN,immunomodulating drugs,advise,Caution_bf exercised_bf administering_bf DRUG therapy_be combination_be immunomodulating_be drugs_be ._be
4398,Prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin.   ,tigecycline,warfarin,advise,Prothrombin_bf time_bf suitable_bf anticoagulation_bf test_bf monitored_bf DRUG administered_be OTHER_DRUG ._af
4441,"However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.",SPIRIVA,anticholinergic,advise,"However_bf ,_bf co_bf administration_bf DRUG OTHER_DRUG containing_af drugs_af (e_af ._af g_af ._af ,_af ipratropium)_af studied_af therefore_af recommended_af ._af"
4442,"However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.",SPIRIVA,ipratropium,advise,"However_bf ,_bf co_bf administration_bf DRUG anticholinergic_be containing_be drugs_be (e_be ._be g_be ._be ,_be ipratropium)_be studied_be therefore_be recommended_be ._be"
4488,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",TOBI,ethacrynic acid,advise,"DRUG administered_be concomitantly_be ethacrynic_be acid_be ,_be furosemide_be ,_be urea_be ,_be mannitol_be ._be"
4489,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",TOBI,furosemide,advise,"DRUG administered_be concomitantly_be ethacrynic_be acid_be ,_be OTHER_DRUG ,_af urea_af ,_af mannitol_af ._af"
4490,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",TOBI,urea,advise,"DRUG administered_be concomitantly_be ethacrynic_be acid_be ,_be furosemide_be ,_be OTHER_DRUG ,_af mannitol_af ._af"
4491,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",TOBI,mannitol,advise,"DRUG administered_be concomitantly_be ethacrynic_be acid_be ,_be furosemide_be ,_be urea_be ,_be OTHER_DRUG ._af"
4502,"Therefore, caution should be exercised when administering TOLECTIN to patients on anticoagulants. ",TOLECTIN,anticoagulants,advise,"Therefore_bf ,_bf caution_bf exercised_bf administering_bf DRUG patients_be OTHER_DRUG ._af"
4509,Caution should be used if TOLECTIN is administered concomitantly with methotrexate. ,TOLECTIN,methotrexate,advise,Caution_bf used_bf DRUG administered_be concomitantly_be OTHER_DRUG ._af
4525,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",ketoconazole,DETROL LA,advise,"For_bf patients_bf receiving_bf DRUG potent_be CYP3A4_be inhibitors_be azole_be antifungals_be (eg_be ,_be itraconazole_be ,_be miconazole)_be macrolide_be antibiotics_be (eg_be ,_be erythromycin_be ,_be clarithromycin)_be cyclosporine_be vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4533,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",azole antifungals,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf vinblastine_bf ,_bf recommended_bf dose_bf DETROL_bf LA_bf 2_bf mg_bf daily_bf ._bf"
4540,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",itraconazole,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf DRUG ,_be miconazole)_be macrolide_be antibiotics_be (eg_be ,_be erythromycin_be ,_be clarithromycin)_be cyclosporine_be vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4546,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",miconazole,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf vinblastine_bf ,_bf recommended_bf dose_bf DETROL_bf LA_bf 2_bf mg_bf daily_bf ._bf"
4551,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",macrolide antibiotics,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf vinblastine_bf ,_bf recommended_bf dose_bf DETROL_bf LA_bf 2_bf mg_bf daily_bf ._bf"
4555,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",erythromycin,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf DRUG ,_be clarithromycin)_be cyclosporine_be vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4558,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",clarithromycin,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf vinblastine_bf ,_bf recommended_bf dose_bf DETROL_bf LA_bf 2_bf mg_bf daily_bf ._bf"
4560,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",cyclosporine,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf DRUG vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4561,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",vinblastine,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf DRUG ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
36,"Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
",S-ketamine,ticlopidine,effect,Exposure_bf oral_bf DRUG unaffected_be itraconazole_be greatly_be increased_be OTHER_DRUG ._af
62,"We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ",DZNep,ABT-737,effect,"We_bf also_bf found_bf Bcl-2_bf overexpressed_bf DRUG insensitive_be cells_be ,_be cotreatment_be DRUG OTHER_DRUG ,_af Bcl-2_af family_af inhibitor_af ,_af synergistically_af inhibited_af growth_af induced_af apoptosis_af DRUG insensitive_af MM_af cells_af ._af"
67,"In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. ",ABT-737,DZNep,effect,"In_bf addition_bf ,_bf OTHER_DRUG insensitivity_be might_be associated_be overexpression_be Bcl-2_be ,_be combination_be DRUG OTHER_DRUG could_af synergistically_af induced_af apoptosis_af ._af"
68,Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.,Implanon,antiretroviral,effect,DRUG failure_be HIV-positive_be woman_be OTHER_DRUG therapy_af resulting_af two_af ectopic_af pregnancies_af ._af
69,We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.,antiretroviral,Implanon,effect,We_bf present_bf interesting_bf case_bf HIV-positive_bf woman_bf DRUG therapy_be tubal_be pregnancies_be two_be separate_be occasions_be OTHER_DRUG place_af ._af
73,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",Warfarin,citalopram,effect,"DRUG users_be increased_be odds_be ratio_be gastrointestinal_be bleeding_be upon_be initiation_be OTHER_DRUG (OR_af =_af 1_af ._af 73_af [95%_af CI_af ,_af 1_af ._af 25-2_af ._af 38])_af ,_af fluoxetine_af (OR_af =_af 1_af ._af 63_af [95%_af CI_af ,_af 1_af ._af 11-2_af ._af 38])_af ,_af paroxetine_af (OR_af =_af 1_af ._af 64_af [95%_af CI_af ,_af 1_af ._af 27-2_af ._af 12])_af ,_af amitriptyline_af (OR_af =_af 1_af ._af 47_af [95%_af CI_af ,_af 1_af ._af 02-2_af ._af 11])_af ._af"
74,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",Warfarin,fluoxetine,effect,"DRUG users_be increased_be odds_be ratio_be gastrointestinal_be bleeding_be upon_be initiation_be citalopram_be (OR_be =_be 1_be ._be 73_be [95%_be CI_be ,_be 1_be ._be 25-2_be ._be 38])_be ,_be OTHER_DRUG (OR_af =_af 1_af ._af 63_af [95%_af CI_af ,_af 1_af ._af 11-2_af ._af 38])_af ,_af paroxetine_af (OR_af =_af 1_af ._af 64_af [95%_af CI_af ,_af 1_af ._af 27-2_af ._af 12])_af ,_af amitriptyline_af (OR_af =_af 1_af ._af 47_af [95%_af CI_af ,_af 1_af ._af 02-2_af ._af 11])_af ._af"
75,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",Warfarin,paroxetine,effect,"DRUG users_be increased_be odds_be ratio_be gastrointestinal_be bleeding_be upon_be initiation_be citalopram_be (OR_be =_be 1_be ._be 73_be [95%_be CI_be ,_be 1_be ._be 25-2_be ._be 38])_be ,_be fluoxetine_be (OR_be =_be 1_be ._be 63_be [95%_be CI_be ,_be 1_be ._be 11-2_be ._be 38])_be ,_be OTHER_DRUG (OR_af =_af 1_af ._af 64_af [95%_af CI_af ,_af 1_af ._af 27-2_af ._af 12])_af ,_af amitriptyline_af (OR_af =_af 1_af ._af 47_af [95%_af CI_af ,_af 1_af ._af 02-2_af ._af 11])_af ._af"
76,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",Warfarin,amitriptyline,effect,"DRUG users_be increased_be odds_be ratio_be gastrointestinal_be bleeding_be upon_be initiation_be citalopram_be (OR_be =_be 1_be ._be 73_be [95%_be CI_be ,_be 1_be ._be 25-2_be ._be 38])_be ,_be fluoxetine_be (OR_be =_be 1_be ._be 63_be [95%_be CI_be ,_be 1_be ._be 11-2_be ._be 38])_be ,_be paroxetine_be (OR_be =_be 1_be ._be 64_be [95%_be CI_be ,_be 1_be ._be 27-2_be ._be 12])_be ,_be OTHER_DRUG (OR_af =_af 1_af ._af 47_af [95%_af CI_af ,_af 1_af ._af 02-2_af ._af 11])_af ._af"
83,"Also mirtazapine, which is not believed to interact with warfarin, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]). ",mirtazapine,warfarin,effect,"Also_bf DRUG ,_be believed_be interact_be OTHER_DRUG ,_af increased_af risk_af GI_af bleeding_af (OR_af =_af 1_af ._af 75_af [95%_af CI_af ,_af 1_af ._af 30-2_af ._af 35])_af ._af"
84,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,citalopram,effect,"DRUG users_be initiated_be OTHER_DRUG ,_af fluoxetine_af ,_af paroxetine_af ,_af amitriptyline_af ,_af mirtazapine_af increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
85,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,fluoxetine,effect,"DRUG users_be initiated_be citalopram_be ,_be OTHER_DRUG ,_af paroxetine_af ,_af amitriptyline_af ,_af mirtazapine_af increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
86,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,paroxetine,effect,"DRUG users_be initiated_be citalopram_be ,_be fluoxetine_be ,_be OTHER_DRUG ,_af amitriptyline_af ,_af mirtazapine_af increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
87,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,amitriptyline,effect,"DRUG users_be initiated_be citalopram_be ,_be fluoxetine_be ,_be paroxetine_be ,_be OTHER_DRUG ,_af mirtazapine_af increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
88,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,mirtazapine,effect,"DRUG users_be initiated_be citalopram_be ,_be fluoxetine_be ,_be paroxetine_be ,_be amitriptyline_be ,_be OTHER_DRUG increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
100,"ABT decreased the toxicity of precocene I, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner. ",ABT,precocene I,effect,"DRUG decreased_be toxicity_be precocene_be I_be ,_be increased_be exposure_be parent_be compound_be ,_be decreased_be metabolite_be levels_be dose-dependent_be manner_be ._be"
113,"Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ",quinidine,precocene I,effect,"Furafylline_bf sulfaphenazole_bf effect_bf ,_bf DRUG appeared_be augment_be precocene_be I_be toxicity_be ._be"
129,AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. ,AAV2,heparinase III,effect,AAV2-mediated_bf retinal_bf transduction_bf improved_bf co-injection_bf heparinase_bf III_bf chondroitin_bf ABC_bf lyase_bf ._bf
130,AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. ,AAV2,chondroitin ABC lyase,effect,AAV2-mediated_bf retinal_bf transduction_bf improved_bf co-injection_bf heparinase_bf III_bf chondroitin_bf ABC_bf lyase_bf ._bf
137,"Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.",ketamine,propofol,effect,"Based_bf experience_bf ,_bf suggest_bf low-dose_bf DRUG added_be OTHER_DRUG may_af associated_af prevention_af EA_af children_af history_af EA_af OTHER_DRUG TIVA_af ._af"
156,"In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ",quinpirole,amphetamine,effect,"In_bf female_bf rats_bf ,_bf neonatal_bf DRUG treatment_be enhanced_be OTHER_DRUG locomotor_af sensitization_af compared_af quinpirole-free_af controls_af sensitized_af OTHER_DRUG ._af"
188,Reduction of PTH by cinacalcet is associated with a decrease in darbepoetin requirement. ,cinacalcet,darbepoetin,effect,Reduction_bf PTH_bf DRUG associated_be decrease_be OTHER_DRUG requirement_af ._af
189,"Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.
",celecoxib,anti-cancer drugs,effect,Interaction_bf DRUG different_be anti-cancer_be drugs_be antagonistic_be breast_be cancer_be cells_be ._be
203,We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. ,celecoxib,doxorubicin,effect,We_bf found_bf antagonism_bf DRUG four_be drugs_be breast_be cancer_be cells_be MCF7_be following_be incubation_be schedules_be DRUG OTHER_DRUG cell_af lines_af except_af two_af combinations_af HCT116_af cells_af ._af
224,The combination of minocycline and fosfomycin can be synergistic against MRSA. ,minocycline,fosfomycin,effect,The_bf combination_bf DRUG OTHER_DRUG synergistic_af MRSA_af ._af
258,"Although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. ",sunitinib,docetaxel,effect,"Although_bf single_bf concurrent_bf use_bf DRUG OTHER_DRUG anti-proliferative_af effects_af ,_af sequential_af administrations_af drugs_af remarkably_af enhanced_af anti-tumor_af activity_af ._af"
259,"When cells were exposed to docetaxel followed by sunitinib, synergism was observed. ",docetaxel,sunitinib,effect,"When_bf cells_bf exposed_bf DRUG followed_be OTHER_DRUG ,_af synergism_af observed_af ._af"
260,The molecular basis of this synergism is that the signaling pathways that were initially activated by docetaxel exposure were efficiently suppressed by the subsequent exposure to sunitinib. ,docetaxel,sunitinib,effect,The_bf molecular_bf basis_bf synergism_bf signaling_bf pathways_bf initially_bf activated_bf DRUG exposure_be efficiently_be suppressed_be subsequent_be exposure_be OTHER_DRUG ._af
265,Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.,docetaxel,sunitinib,effect,OTHER_DRUG single_be agent_be exhibits_be anti-proliferative_be effects_be vitro_be NSCLC_be cell_be lines_be EGFR_be T790M_be K-ras_be mutations_be sequential_be administration_be DRUG followed_af OTHER_DRUG superior_af OTHER_DRUG followed_af DRUG concurrent_af administration_af ._af
278,Distinct and statistically significant synergism was observed between methylglyoxal and piperacillin by disc diffusion tests when compared with their individual effects. ,methylglyoxal,piperacillin,effect,Distinct_bf statistically_bf significant_bf synergism_bf observed_bf DRUG OTHER_DRUG disc_af diffusion_af tests_af compared_af individual_af effects_af ._af
279,Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.,methylglyoxal,carbenicillin,effect,Synergism_bf also_bf noted_bf DRUG combined_be OTHER_DRUG amikacin_af ._af
280,Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.,methylglyoxal,amikacin,effect,Synergism_bf also_bf noted_bf DRUG combined_be carbenicillin_be OTHER_DRUG ._af
283,"(ii) acetyl-l-carnitine elicits a significant protective effect on DEB induced toxicity, which was potentiated by  alpha-lipoic acid.",acetyl-l-carnitine,alpha-lipoic acid,effect,"(ii)_bf DRUG elicits_be significant_be protective_be effect_be DEB_be induced_be toxicity_be ,_be potentiated_be alpha-lipoic_be acid_be ._be"
294,"Acute administration of hemantane or doxycycline failed to influence locomotion in mice, while their combination normalized motor activity. ",hemantane,doxycycline,effect,"Acute_bf administration_bf DRUG OTHER_DRUG failed_af influence_af locomotion_af mice_af ,_af combination_af normalized_af motor_af activity_af ._af"
295,"The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
",dasatinib,paclitaxel,effect,The_bf role_bf p27(Kip1)_bf dasatinib-enhanced_bf OTHER_DRUG cytotoxicity_be human_be ovarian_be cancer_be cells_be ._be
298,HEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone. ,dasatinib,paclitaxel,effect,HEY_bf cells_bf treated_bf DRUG plus_be OTHER_DRUG formed_af fewer_af colonies_af cells_af treated_af either_af agent_af alone_af ._af
299,"Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",dasatinib,paclitaxel,effect,"Treatment_bf HEY_bf xenograft-bearing_bf mice_bf DRUG plus_be OTHER_DRUG inhibited_af tumor_af growth_af treatment_af either_af agent_af alone_af (average_af tumor_af volume_af per_af mouse_af ,_af DRUG +_af OTHER_DRUG vs_af paclitaxel:_af 0_af ._af 28_af vs_af ._af 0_af ._af 81_af cm3_af ,_af difference_af =_af 0_af ._af 53_af cm3_af ,_af 95%_af confidence_af interval_af [CI]_af =_af 0_af ._af 44_af 0_af ._af 62_af cm3_af ,_af P_af =_af ._af 014);_af"
311,Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. ,dasatinib,paclitaxel,effect,Studies_bf forced_bf expression_bf siRNA_bf knockdown_bf Bcl-2_bf Cdk1_bf suggest_bf dasatinib-mediated_bf induction_bf p27(Kip1)_bf enhanced_bf paclitaxel-induced_bf apoptosis_bf negatively_bf regulating_bf Bcl-2_bf Cdk1_bf expression_bf ._bf
312,Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.,dasatinib,paclitaxel,effect,Inhibition_bf Src_bf family_bf Abl_bf kinases_bf either_bf siRNAs_bf DRUG enhances_be OTHER_DRUG sensitivity_af ovarian_af cancer_af cells_af p27(Kip1)-mediated_af suppression_af Bcl-2_af Cdk1_af expression_af ._af
319,The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM.,lenalidomide,CCI-779,effect,The_bf preclinical_bf combination_bf DRUG mTOR_be inhibitor_be OTHER_DRUG displayed_af synergy_af vitro_af represents_af novel_af combination_af MM_af ._af
328,"In experiment 2, the same regimen of GSLS was administered to chickens inoculated with inactivated AI vaccines, and an enhanced serum antibody response to AI vaccination was also observed. ",GSLS,inactivated AI vaccines,effect,"In_bf experiment_bf 2_bf ,_bf regimen_bf DRUG administered_be chickens_be inoculated_be inactivated_be AI_be vaccines_be ,_be enhanced_be serum_be antibody_be response_be AI_be vaccination_be also_be observed_be ._be"
336,Imexon and dacarbazine show additive effects in vitro but not in vivo in human A375 melanoma cells.,Imexon,dacarbazine,effect,DRUG OTHER_DRUG show_af additive_af effects_af vitro_af vivo_af human_af A375_af melanoma_af cells_af ._af
341,"CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. ",CRM197,doxorubicin,effect,"DRUG induced_be apoptosis_be ,_be furthermore_be ,_be combination_be DRUG plus_af OTHER_DRUG enhanced_af cytotoxicity_af T-ALL_af cell_af line_af ._af"
342,"Ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.
",Ephedrine,dexmedetomidine,effect,DRUG enhances_be antinociceptive_be effect_be OTHER_DRUG mice_af ._af
350,"In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. ",dexmedetomidine,ephedrine,effect,"In_bf hot_bf plate_bf test_bf mice_bf ,_bf co-administration_bf 15_bf g/kg_bf DRUG 10_be mg/kg_be OTHER_DRUG intraperitoneally_af enhanced_af ,_af also_af prolonged_af duration_af antinociception_af induced_af DRUG ._af"
353,"At the same time, the locomotor inhibitory effect of dexmedetomidine was counteracted by ephedrine. ",dexmedetomidine,ephedrine,effect,"At_bf time_bf ,_bf locomotor_bf inhibitory_bf effect_bf DRUG counteracted_be OTHER_DRUG ._af"
354,"We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.",dexmedetomidine,ephedrine,effect,"We_bf concluded_bf combined_bf administration_bf DRUG OTHER_DRUG may_af beneficial_af effects_af treatment_af pain_af without_af causing_af sedation_af ,_af limits_af use_af DRUG analgesic_af humans_af ._af"
364,"But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ",amlodipine,valsartan,effect,"But_bf use_bf fixed_bf combination_bf amlodipine/valsartan_bf compared_bf traditional_bf therapy_bf associated_bf lower_bf clinical_bf self_bf measured_bf BP_bf ,_bf quicker_bf achievement_bf target_bf BP_bf (5_bf ._bf 8+/-2_bf ._bf 3_bf 9_bf ._bf 2+/-1_bf ._bf 8_bf days_bf ,_bf respectively_bf ,_bf 0_bf ._bf 05)_bf ,_bf lesser_bf number_bf antihypertensive_bf drugs_bf (2_bf ._bf 5+/-0_bf ._bf 6_bf 3_bf ._bf 0+/-0_bf ._bf 9_bf days_bf ,_bf respectively)_bf ,_bf lower_bf rate_bf concealed_bf inefficacy_bf treatment_bf (12_bf 31%_bf ,_bf respectively_bf ,_bf 0_bf ._bf 05)_bf ._bf"
367,"We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.",amlodipine,valsartan,effect,"We_bf demonstrated_bf appropriateness_bf inhospital_bf administration_bf fixed_bf amlodipine/valsartan_bf combination_bf approach_bf allowing_bf achieve_bf target_bf BP_bf shorter_bf time_bf ,_bf use_bf fewer_bf antihypertensive_bf drugs_bf ,_bf diminishing_bf concealed_bf inefficacy_bf treatment_bf ._bf"
378,"The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",ticagrelor,aspirin,effect,"The_bf FDA_bf approved_bf DRUG (Brilinta-AstraZeneca)_be ,_be oral_be antiplatelet_be drug_be ,_be use_be low-dose_be OTHER_DRUG reduce_af rate_af thrombotic_af cardiovascular_af events_af patients_af acute_af coronary_af syndrome_af (ACS)_af ._af"
380,"The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",Brilinta,aspirin,effect,"The_bf FDA_bf approved_bf ticagrelor_bf (Brilinta-AstraZeneca)_bf ,_bf oral_bf antiplatelet_bf drug_bf ,_bf use_bf low-dose_bf OTHER_DRUG reduce_be rate_be thrombotic_be cardiovascular_be events_be patients_be acute_be coronary_be syndrome_be (ACS)_be ._be"
414,The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction. ,ezetimibe,cholestyramine,effect,The_bf incremental_bf LDL-C_bf reduction_bf due_bf adding_bf DRUG OTHER_DRUG may_af reduced_af interaction_af ._af
469,"The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.",Mecamylamine,antihypertensive drugs,effect,"The_bf action_bf DRUG may_be potentiated_be anesthesia_be ,_be antihypertensive_be drugs_be alcohol_be ._be"
470,"The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.",Mecamylamine,alcohol,effect,"The_bf action_bf DRUG may_be potentiated_be anesthesia_be ,_be antihypertensive_be drugs_be OTHER_DRUG ._af"
603,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,progestin,effect,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
621,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,corticosteroids,effect,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
626,ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors. ,NSAIDs,angiotensin-converting enzyme (ACE) inhibitors,effect,ACE_bf inhibitors_bf Reports_bf suggest_bf DRUG may_be diminish_be antihypertensive_be effect_be angiotensin-converting_be enzyme_be (ACE)_be inhibitors_be ._be
634,"Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. ",aspirin,MOBIC,effect,"Concomitant_bf administration_bf low-dose_bf DRUG OTHER_DRUG may_af result_af increased_af rate_af GI_af ulceration_af complications_af ,_af compared_af use_af OTHER_DRUG alone_af ._af"
651,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ",NSAIDs,furosemide,effect,"Furosemide:_bf Clinical_bf studies_bf ,_bf well_bf post-marketing_bf observations_bf ,_bf shown_bf DRUG reduce_be natriuretic_be effect_be OTHER_DRUG thiazide_af diuretics_af patients_af ._af"
652,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ",NSAIDs,thiazide diuretics,effect,"Furosemide:_bf Clinical_bf studies_bf ,_bf well_bf post-marketing_bf observations_bf ,_bf shown_bf DRUG reduce_be natriuretic_be effect_be furosemide_be thiazide_be diuretics_be patients_be ._be"
692,DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,Nalidixic acid,melphalan,effect,DRUG_bf INTERACTIONS_bf There_bf known_bf drug/drug_bf interactions_bf oral_bf ALKERAN_bf Vaccinations_bf live_bf organism_bf vaccines_bf recommended_bf immunocompromised_bf individuals_bf Nalidixic_bf acid_bf together_bf high-dose_bf intravenous_bf OTHER_DRUG caused_be deaths_be children_be due_be haemorrhagic_be enterocolitis_be ._be
693,Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous melphalan and who subsequently received cyclosporin to prevent graft-versus-host disease,melphalan,cyclosporin,effect,Impaired_bf renal_bf function_bf described_bf bone_bf marrow_bf transplant_bf patients_bf conditioned_bf high-dose_bf intravenous_bf DRUG subsequently_be received_be OTHER_DRUG prevent_af graft-versus-host_af disease_af
694,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,amantadine,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf OTHER_DRUG ,_be antiarrhythmic_be agents_be class_be I_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be antihistamines_be ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
695,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,antiarrhythmic agents of class I,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
696,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,quinidine,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
697,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,antihistamines,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf OTHER_DRUG ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
698,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,antipsychotic agents,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
699,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,phenothiazines,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
700,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,benzodiazepines,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf OTHER_DRUG ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
701,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,MAO inhibitors,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
702,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,narcotic analgesics,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
703,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,meperidine,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
704,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,nitrates,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf OTHER_DRUG nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
705,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,nitrites,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf OTHER_DRUG ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
706,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,sympathomimetic agents,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
707,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,tricyclic antidepressants,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
799,Anticholinergics antagonize the effects of antiglaucoma agents. ,Anticholinergics,antiglaucoma agents,effect,DRUG antagonize_be effects_be antiglaucoma_be agents_be ._be
800,Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. ,Anticholinergic drugs,corticosteroids,effect,Anticholinergic_bf drugs_bf presence_bf increased_bf intraocular_bf pressure_bf may_bf hazardous_bf taken_bf concurrently_bf agents_bf OTHER_DRUG ._be
802,"Anticholinergic drugs may antagonize the effects of drugs that alter gastrointestinal motility, such as metoclopramide. ",Anticholinergic drugs,metoclopramide,effect,"Anticholinergic_bf drugs_bf may_bf antagonize_bf effects_bf drugs_bf alter_bf gastrointestinal_bf motility_bf ,_bf OTHER_DRUG ._be"
804,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",SKELAXIN,alcohol,effect,"DRUG may_be enhance_be effects_be OTHER_DRUG ,_af barbiturates_af CNS_af depressants_af ._af"
805,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",SKELAXIN,barbiturates,effect,"DRUG may_be enhance_be effects_be alcohol_be ,_be OTHER_DRUG CNS_af depressants_af ._af"
806,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",SKELAXIN,CNS depressants,effect,"DRUG may_be enhance_be effects_be alcohol_be ,_be barbiturates_be CNS_be depressants_be ._be"
815,"Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.",aspirin,carbonic anhydrase inhibitors,effect,"Caution_bf advised_bf patients_bf receiving_bf high-dose_bf DRUG methazolamide_be concomitantly_be ,_be anorexia_be ,_be tachypnea_be ,_be lethargy_be ,_be coma_be death_be reported_be concomitant_be use_be high-dose_be DRUG carbonic_af anhydrase_af inhibitors_af ._af"
818,Anticoagulants (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole.    ,anticoagulants,methimazole,effect,DRUG (oral):_be The_be activity_be oral_be DRUG may_af potentiated_af anti-vitamin-K_af activity_af attributed_af OTHER_DRUG ._af
823,"Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. ",opioids,levomepromazine,effect,"Dosages_bf concomitantly_bf administered_bf DRUG reduced_be approximately_be half_be ,_be OTHER_DRUG amplifies_af therapeutic_af actions_af side-effects_af DRUG ._af"
825,"Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. ",levomepromazine,opioids,effect,"Dosages_bf concomitantly_bf administered_bf OTHER_DRUG reduced_be approximately_be half_be ,_be DRUG amplifies_af therapeutic_af actions_af side-effects_af OTHER_DRUG ._af"
827,Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates. ,levomepromazine,benzodiazepines,effect,Additive_bf sedative_bf effects_bf confusional_bf states_bf may_bf emerge_bf DRUG given_be OTHER_DRUG barbiturates_af ._af
828,Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates. ,levomepromazine,barbiturates,effect,Additive_bf sedative_bf effects_bf confusional_bf states_bf may_bf emerge_bf DRUG given_be benzodiazepines_be OTHER_DRUG ._af
838,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,Caffeine,levomepromazine,effect,DRUG and/or_be stimulantes_be ephedrine/amphetamine_be type_be may_be counteract_be specific_be actions_be OTHER_DRUG ._af
840,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,ephedrine,levomepromazine,effect,Caffeine_bf and/or_bf stimulantes_bf ephedrine/amphetamine_bf type_bf may_bf counteract_bf specific_bf actions_bf OTHER_DRUG ._be
841,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,amphetamine,levomepromazine,effect,Caffeine_bf and/or_bf stimulantes_bf ephedrine/amphetamine_bf type_bf may_bf counteract_bf specific_bf actions_bf OTHER_DRUG ._be
858,Thiazides may decrease arterial responsiveness to norepinephrine. ,Thiazides,norepinephrine,effect,DRUG may_be decrease_be arterial_be responsiveness_be OTHER_DRUG ._af
859,Thiazide drugs may increase the responsiveness of tubocurarine. ,Thiazide drugs,tubocurarine,effect,Thiazide_bf drugs_bf may_bf increase_bf responsiveness_bf OTHER_DRUG ._be
863,Thiazides may add to or potentiate the action of other antihypertensive drugs. ,Thiazides,antihypertensive drugs,effect,DRUG may_be add_be potentiate_be action_be antihypertensive_be drugs_be ._be
865,"When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. ",methyldopa,antihypertensive drugs,effect,"When_bf DRUG used_be antihypertensive_be drugs_be ,_be potentiation_be antihypertensive_be effect_be may_be occur_be ._be"
1014,Ritalin may decrease the hypotensive effect of guanethidine. ,Ritalin,guanethidine,effect,DRUG may_be decrease_be hypotensive_be effect_be OTHER_DRUG ._af
1074,convulsions have been reported with concurrent use of methylprednisolone and cyclosporin. ,methylprednisolone,cyclosporin,effect,convulsions_bf reported_bf concurrent_bf use_bf DRUG OTHER_DRUG ._af
1091,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. ,salicylate,methylprednisolone,effect,This_bf could_bf lead_bf decreased_bf DRUG serum_be levels_be increase_be risk_be DRUG toxicity_af OTHER_DRUG withdrawn_af ._af
1094,There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids. ,anticoagulant,corticosteroids,effect,There_bf reports_bf enhanced_bf well_bf diminished_bf effects_bf DRUG given_be concurrently_be OTHER_DRUG ._af
1349,Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.,alcohol,methyprylon,effect,Concurrent_bf use_bf DRUG CNS_be depression-producing_be drugs_be may_be increase_be CNS_be depressant_be effects_be OTHER_DRUG medications_af ._af
1350,Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.,CNS depression-producing drugs,methyprylon,effect,Concurrent_bf use_bf alcohol_bf CNS_bf depression-producing_bf drugs_bf may_bf increase_bf CNS_bf depressant_bf effects_bf OTHER_DRUG medications_be ._be
1351,Methysergide may reverse the analgesic activity of narcotic analgesics. ,Methysergide,narcotic analgesics,effect,DRUG may_be reverse_be analgesic_be activity_be narcotic_be analgesics_be ._be
1358,The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. ,metoclopramide,anticholinergic drugs,effect,The_bf effects_bf DRUG gastrointestinal_be motility_be antagonized_be anticholinergic_be drugs_be narcotic_be analgesics_be ._be
1359,The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. ,metoclopramide,narcotic analgesics,effect,The_bf effects_bf DRUG gastrointestinal_be motility_be antagonized_be anticholinergic_be drugs_be narcotic_be analgesics_be ._be
1361,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,alcohol,effect,"Additive_bf sedative_bf effects_bf occur_bf DRUG given_be OTHER_DRUG ,_af sedatives_af ,_af hypnotics_af ,_af narcotics_af ,_af tranquilizers_af ._af"
1362,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,sedatives,effect,"Additive_bf sedative_bf effects_bf occur_bf DRUG given_be alcohol_be ,_be OTHER_DRUG ,_af hypnotics_af ,_af narcotics_af ,_af tranquilizers_af ._af"
1363,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,hypnotics,effect,"Additive_bf sedative_bf effects_bf occur_bf DRUG given_be alcohol_be ,_be sedatives_be ,_be OTHER_DRUG ,_af narcotics_af ,_af tranquilizers_af ._af"
1364,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,narcotics,effect,"Additive_bf sedative_bf effects_bf occur_bf DRUG given_be alcohol_be ,_be sedatives_be ,_be hypnotics_be ,_be OTHER_DRUG ,_af tranquilizers_af ._af"
1365,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,tranquilizers,effect,"Additive_bf sedative_bf effects_bf occur_bf DRUG given_be alcohol_be ,_be sedatives_be ,_be hypnotics_be ,_be narcotics_be ,_be OTHER_DRUG ._af"
1399,"Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. ",metronidazole,coumarin,effect,"Oral_bf DRUG reported_be potentiate_be anticoagulant_be effect_be OTHER_DRUG warfarin_af ,_af resulting_af prolongation_af prothrombin_af time_af ._af"
1400,"Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. ",metronidazole,warfarin,effect,"Oral_bf DRUG reported_be potentiate_be anticoagulant_be effect_be coumarin_be OTHER_DRUG ,_af resulting_af prolongation_af prothrombin_af time_af ._af"
1407,Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.,Metopirone,acetaminophen,effect,DRUG inhibits_be glucuronidation_be OTHER_DRUG could_af possibly_af potentiate_af OTHER_DRUG toxicity_af ._af
1412,Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.,DEMSER,alcohol,effect,Concurrent_bf use_bf DRUG OTHER_DRUG CNS_af depressants_af increase_af sedative_af effects_af ._af
1413,Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.,DEMSER,CNS depressants,effect,Concurrent_bf use_bf DRUG alcohol_be CNS_be depressants_be increase_be sedative_be effects_be ._be
1634,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,narcotics,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf OTHER_DRUG (eg_be ,_be morphine_be ,_be meperidine_be fentanyl)_be ,_be propofol_be ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
1635,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,morphine,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf OTHER_DRUG ,_be meperidine_be fentanyl)_be ,_be propofol_be ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
1636,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,meperidine,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf OTHER_DRUG fentanyl)_be ,_be propofol_be ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
1637,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,fentanyl,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf ketamine_bf ,_bf nitrous_bf oxide_bf ,_bf secobarbital_bf droperidol_bf ._bf"
1638,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,propofol,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf OTHER_DRUG ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
1639,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,ketamine,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf OTHER_DRUG ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
1640,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,nitrous oxide,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf ketamine_bf ,_bf nitrous_bf oxide_bf ,_bf secobarbital_bf droperidol_bf ._bf"
1641,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,secobarbital,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf ketamine_bf ,_bf nitrous_bf oxide_bf ,_bf OTHER_DRUG droperidol_be ._be"
1642,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,droperidol,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf ketamine_bf ,_bf nitrous_bf oxide_bf ,_bf secobarbital_bf OTHER_DRUG ._be"
1700,"When administered concomitantly with ProAmatine   , cardiac glycosides may enhance or precipitate bradycardia, A.V. ",ProAmatine,cardiac glycosides,effect,"When_bf administered_bf concomitantly_bf DRUG ,_be cardiac_be glycosides_be may_be enhance_be precipitate_be bradycardia_be ,_be A_be ._be V_be ._be"
1705,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",phenylephrine,ProAmatine,effect,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be pseudoephedrine_be ,_be ephedrine_be ,_be phenylpropanolamine_be dihydroergotamine)_be may_be enhance_be potentiate_be pressor_be effects_be OTHER_DRUG ._af Therefore_af ,_af caution_af used_af OTHER_DRUG administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1710,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",pseudoephedrine,ProAmatine,effect,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf DRUG ,_be ephedrine_be ,_be phenylpropanolamine_be dihydroergotamine)_be may_be enhance_be potentiate_be pressor_be effects_be OTHER_DRUG ._af Therefore_af ,_af caution_af used_af OTHER_DRUG administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1714,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",ephedrine,ProAmatine,effect,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf pseudoephedrine_bf ,_bf DRUG ,_be phenylpropanolamine_be dihydroergotamine)_be may_be enhance_be potentiate_be pressor_be effects_be OTHER_DRUG ._af Therefore_af ,_af caution_af used_af OTHER_DRUG administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1717,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",phenylpropanolamine,ProAmatine,effect,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf pseudoephedrine_bf ,_bf ephedrine_bf ,_bf DRUG dihydroergotamine)_be may_be enhance_be potentiate_be pressor_be effects_be OTHER_DRUG ._af Therefore_af ,_af caution_af used_af OTHER_DRUG administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1719,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",dihydroergotamine,ProAmatine,effect,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf pseudoephedrine_bf ,_bf ephedrine_bf ,_bf phenylpropanolamine_bf dihydroergotamine)_bf may_bf enhance_bf potentiate_bf pressor_bf effects_bf OTHER_DRUG ._be Therefore_be ,_be caution_be used_be OTHER_DRUG administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1739,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",Alpha-adrenergic blocking agents,ProAmatine,effect,"OTHER_DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be OTHER_DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1750,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",prazosin,ProAmatine,effect,"OTHER_DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be DRUG ,_af terazosin_af ,_af doxazosin_af ,_af antagonize_af effects_af OTHER_DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1760,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",terazosin,ProAmatine,effect,"OTHER_DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be DRUG ,_af doxazosin_af ,_af antagonize_af effects_af OTHER_DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1769,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",doxazosin,ProAmatine,effect,"OTHER_DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be DRUG ,_af antagonize_af effects_af OTHER_DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1867,The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. ,tetracycline,methoxyflurane,effect,The_bf concurrent_bf use_bf DRUG OTHER_DRUG reported_af result_af fatal_af renal_af toxicity_af ._af
1868,Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.,tetracyclines,contraceptives,effect,Concurrent_bf use_bf DRUG oral_be OTHER_DRUG may_af render_af oral_af OTHER_DRUG less_af effective_af ._af
1873,"Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. ",minoxidil,guanethidine,effect,"Interaction_bf Guanethidine:_bf Although_bf DRUG cause_be orthostatic_be hypotension_be ,_be administration_be patients_be already_be receiving_be OTHER_DRUG result_af profound_af orthostatic_af effects_af ._af"
1882,"However, the impairment of cognitive and motor skills produced by REMERON    were shown to be additive with those produced by alcohol. ",REMERON,alcohol,effect,"However_bf ,_bf impairment_bf cognitive_bf motor_bf skills_bf produced_bf DRUG shown_be additive_be produced_be OTHER_DRUG ._af"
1893,"However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam. ",REMERON,diazepam,effect,"However_bf ,_bf impairment_bf motor_bf skills_bf produced_bf DRUG shown_be additive_be caused_be OTHER_DRUG ._af"
1904,Prior administration of succinylcholine can potentiate the neuromuscular blocking effects of nondepolarizing agents. ,succinylcholine,nondepolarizing agents,effect,Prior_bf administration_bf DRUG potentiate_be neuromuscular_be blocking_be effects_be nondepolarizing_be agents_be ._be
2039,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",MIVACRON,contraceptives,effect,"The_bf neuromuscular_bf blocking_bf effect_bf DRUG may_be enhanced_be drugs_be reduce_be plasma_be cholinesterase_be activity_be (e_be ._be g_be ._be ,_be chronically_be administered_be oral_be OTHER_DRUG ,_af glucocorticoids_af ,_af certain_af monoamine_af oxidase_af inhibitors)_af drugs_af irreversibly_af inhibit_af plasma_af cholinesterase_af ._af Resistance_af neuromuscular_af blocking_af action_af nondepolarizing_af neuromuscular_af blocking_af agents_af demonstrated_af patients_af chronically_af administered_af phenytoin_af carbamazepine_af ._af"
2040,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",MIVACRON,glucocorticoids,effect,"The_bf neuromuscular_bf blocking_bf effect_bf DRUG may_be enhanced_be drugs_be reduce_be plasma_be cholinesterase_be activity_be (e_be ._be g_be ._be ,_be chronically_be administered_be oral_be contraceptives_be ,_be OTHER_DRUG ,_af certain_af monoamine_af oxidase_af inhibitors)_af drugs_af irreversibly_af inhibit_af plasma_af cholinesterase_af ._af Resistance_af neuromuscular_af blocking_af action_af nondepolarizing_af neuromuscular_af blocking_af agents_af demonstrated_af patients_af chronically_af administered_af phenytoin_af carbamazepine_af ._af"
2041,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",MIVACRON,monoamine oxidase inhibitors,effect,"The_bf neuromuscular_bf blocking_bf effect_bf DRUG may_be enhanced_be drugs_be reduce_be plasma_be cholinesterase_be activity_be (e_be ._be g_be ._be ,_be chronically_be administered_be oral_be contraceptives_be ,_be glucocorticoids_be ,_be certain_be monoamine_be oxidase_be inhibitors)_be drugs_be irreversibly_be inhibit_be plasma_be cholinesterase_be ._be Resistance_be neuromuscular_be blocking_be action_be nondepolarizing_be neuromuscular_be blocking_be agents_be demonstrated_be patients_be chronically_be administered_be phenytoin_be carbamazepine_be ._be"
2057,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",neuromuscular blocking agents,phenytoin,effect,"The_bf neuromuscular_bf blocking_bf effect_bf MIVACRON_bf may_bf enhanced_bf drugs_bf reduce_bf plasma_bf cholinesterase_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf chronically_bf administered_bf oral_bf contraceptives_bf ,_bf glucocorticoids_bf ,_bf certain_bf monoamine_bf oxidase_bf inhibitors)_bf drugs_bf irreversibly_bf inhibit_bf plasma_bf cholinesterase_bf ._bf Resistance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf neuromuscular_bf blocking_bf agents_bf demonstrated_bf patients_bf chronically_bf administered_bf OTHER_DRUG carbamazepine_be ._be"
2058,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",neuromuscular blocking agents,carbamazepine,effect,"The_bf neuromuscular_bf blocking_bf effect_bf MIVACRON_bf may_bf enhanced_bf drugs_bf reduce_bf plasma_bf cholinesterase_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf chronically_bf administered_bf oral_bf contraceptives_bf ,_bf glucocorticoids_bf ,_bf certain_bf monoamine_bf oxidase_bf inhibitors)_bf drugs_bf irreversibly_bf inhibit_bf plasma_bf cholinesterase_bf ._bf Resistance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf neuromuscular_bf blocking_bf agents_bf demonstrated_bf patients_bf chronically_bf administered_bf phenytoin_bf OTHER_DRUG ._be"
2061,"While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",phenytoin,MIVACRON,effect,"While_bf effects_bf chronic_bf DRUG carbamazepine_be therapy_be action_be OTHER_DRUG unknown_af ,_af slightly_af shorter_af durations_af neuromuscular_af block_af may_af anticipated_af infusion_af rate_af requirements_af may_af higher_af ._af"
2062,"While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",carbamazepine,MIVACRON,effect,"While_bf effects_bf chronic_bf phenytoin_bf DRUG therapy_be action_be OTHER_DRUG unknown_af ,_af slightly_af shorter_af durations_af neuromuscular_af block_af may_af anticipated_af infusion_af rate_af requirements_af may_af higher_af ._af"
2165,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",potassium-sparing diuretics,ACE inhibitors,effect,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf triamterene_bf ,_bf amiloride)_bf potassium_bf supplements_bf concomitantly_bf ACE_bf inhibitors_bf increase_bf risk_bf hyperkalemia_bf ._bf"
2169,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",spironolactone,ACE inhibitors,effect,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf triamterene_bf ,_bf amiloride)_bf potassium_bf supplements_bf concomitantly_bf ACE_bf inhibitors_bf increase_bf risk_bf hyperkalemia_bf ._bf"
2172,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",triamterene,ACE inhibitors,effect,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf DRUG ,_be amiloride)_be potassium_be supplements_be concomitantly_be ACE_be inhibitors_be increase_be risk_be hyperkalemia_be ._be"
2174,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",amiloride,ACE inhibitors,effect,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf triamterene_bf ,_bf amiloride)_bf potassium_bf supplements_bf concomitantly_bf ACE_bf inhibitors_bf increase_bf risk_bf hyperkalemia_bf ._bf"
2175,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",potassium,ACE inhibitors,effect,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf triamterene_bf ,_bf amiloride)_bf DRUG supplements_be concomitantly_be ACE_be inhibitors_be increase_be risk_be hyperkalemia_be ._be"
2188,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,ACE inhibitors,lithium,effect,Lithium:_bf Increased_bf serum_bf OTHER_DRUG levels_be symptoms_be OTHER_DRUG toxicity_af reported_af patients_af receiving_af ACE_af inhibitors_af therapy_af OTHER_DRUG ._af
2189,"If a diuretic is also used, the risk of lithium toxicity may be increased. ",diuretic,lithium,effect,"If_bf DRUG also_be used_be ,_be risk_be OTHER_DRUG toxicity_af may_af increased_af ._af"
2302,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,CNS depressants,effect,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf DRUG potentiated_be presence_be CNS_be depressants_be alcohol_be ,_be sedatives_be ,_be antihistaminics_be ,_be psychotropic_be drugs_be ._be"
2303,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,alcohol,effect,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf DRUG potentiated_be presence_be CNS_be depressants_be OTHER_DRUG ,_af sedatives_af ,_af antihistaminics_af ,_af psychotropic_af drugs_af ._af"
2304,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,sedatives,effect,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf DRUG potentiated_be presence_be CNS_be depressants_be alcohol_be ,_be OTHER_DRUG ,_af antihistaminics_af ,_af psychotropic_af drugs_af ._af"
2305,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,antihistaminics,effect,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf DRUG potentiated_be presence_be CNS_be depressants_be alcohol_be ,_be sedatives_be ,_be OTHER_DRUG ,_af psychotropic_af drugs_af ._af"
2306,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,psychotropic drugs,effect,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf DRUG potentiated_be presence_be CNS_be depressants_be alcohol_be ,_be sedatives_be ,_be antihistaminics_be ,_be psychotropic_be drugs_be ._be"
2317,"Use of neuroleptics in conjunction with oral morphine may increase the risk of respiratory depression, hypotension and profound sedation or coma. ",neuroleptics,morphine,effect,"Use_bf DRUG conjunction_be oral_be OTHER_DRUG may_af increase_af risk_af respiratory_af depression_af ,_af hypotension_af profound_af sedation_af coma_af ._af"
2450,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",ondansetron,tramadol,effect,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf DRUG recommended_be patients_be drugs_be ._be 1_be ,_be 3_be Tramadol:_be Although_be pharmacokinetic_be drug_be interaction_be DRUG OTHER_DRUG observed_af ,_af data_af 2_af small_af studies_af indicate_af DRUG may_af associated_af increase_af patient_af controlled_af administration_af OTHER_DRUG ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af DRUG ._af"
2553,"Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.",Tetracycline,penicillin,effect,"DRUG ,_be bacteriostatic_be antibiotic_be ,_be may_be antagonize_be bactericidal_be effect_be OTHER_DRUG concurrent_af use_af drugs_af avoided_af ._af"
2559,Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants. ,Anabolic steroids,anticoagulants,effect,OTHER_DRUG Anabolic_be steroids_be may_be increase_be sensitivity_be oral_be OTHER_DRUG ._af
2584,"The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. ",oxybutynin,anticholinergic drugs,effect,"The_bf concomitant_bf use_bf DRUG anticholinergic_be drugs_be agents_be produce_be dry_be mouth_be ,_be constipation_be ,_be somnolence_be (drowsiness)_be ,_be and/or_be anticholinergic-like_be effects_be may_be increase_be frequency_be and/or_be severity_be effects_be ._be"
2630,The CNS depressant effects of oxycodone hydrochloride may be additive with that of other CNS depressants..,oxycodone hydrochloride,CNS depressants,effect,The_bf CNS_bf depressant_bf effects_bf oxycodone_bf hydrochloride_bf may_bf additive_bf CNS_bf depressants_bf ._bf ._bf
2676,"Anticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. ",Anticholinergics,opioid analgesics,effect,"DRUG medications_be anticholinergic_be activity_be used_be concurrently_be opioid_be analgesics_be may_be result_be increased_be risk_be urinary_be retention_be and/or_be severe_be constipation_be ,_be may_be lead_be paralytic_be ileus_be ._be"
2677,It has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia. ,oxymorphone,propofol,effect,It_bf reported_bf incidence_bf bradycardia_bf increased_bf DRUG combined_be OTHER_DRUG induction_af anesthesia_af ._af
2678,"In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of cimetidine with opioid analgesics; ",cimetidine,opioid analgesics,effect,"In_bf addition_bf ,_bf CNS_bf toxicity_bf reported_bf (confusion_bf ,_bf disorientation_bf ,_bf respiratory_bf depression_bf ,_bf apnea_bf ,_bf seizures)_bf following_bf coadministration_bf DRUG opioid_be analgesics;_be"
2686,Paliperidone may antagonize the effect of levodopa and other dopamine agonists. ,Paliperidone,levodopa,effect,DRUG may_be antagonize_be effect_be OTHER_DRUG dopamine_af agonists_af ._af
2687,Paliperidone may antagonize the effect of levodopa and other dopamine agonists. ,Paliperidone,dopamine agonists,effect,DRUG may_be antagonize_be effect_be levodopa_be dopamine_be agonists_be ._be
2992,"There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. ",proton pump inhibitors,warfarin,effect,"There_bf postmarketing_bf reports_bf increased_bf INR_bf prothrombin_bf time_bf patients_bf receiving_bf proton_bf pump_bf inhibitors_bf ,_bf including_bf pantoprazole_bf ,_bf OTHER_DRUG concomitantly_be ._be"
2993,"There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. ",pantoprazole,warfarin,effect,"There_bf postmarketing_bf reports_bf increased_bf INR_bf prothrombin_bf time_bf patients_bf receiving_bf proton_bf pump_bf inhibitors_bf ,_bf including_bf DRUG ,_be OTHER_DRUG concomitantly_af ._af"
3139,Decreased seizure threshold has been reported in patients receiving CYLERT concomitantly with antiepileptic medications.,CYLERT,antiepileptic medications,effect,Decreased_bf seizure_bf threshold_bf reported_bf patients_bf receiving_bf DRUG concomitantly_be antiepileptic_be medications_be ._be
21,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Moxifloxacin,sucralfate,mechanism,DRUG Lomefloxacin_be reacts_be faster_be OTHER_DRUG gelusil_af acidic_af media_af whereas_af erythromycin_af basic_af media_af multi-minerals_af neutral_af media_af ._af
22,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Moxifloxacin,gelusil,mechanism,DRUG Lomefloxacin_be reacts_be faster_be sucralfate_be OTHER_DRUG acidic_af media_af whereas_af erythromycin_af basic_af media_af multi-minerals_af neutral_af media_af ._af
23,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Moxifloxacin,erythromycin,mechanism,DRUG Lomefloxacin_be reacts_be faster_be sucralfate_be gelusil_be acidic_be media_be whereas_be OTHER_DRUG basic_af media_af multi-minerals_af neutral_af media_af ._af
24,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Moxifloxacin,multi-minerals,mechanism,DRUG Lomefloxacin_be reacts_be faster_be sucralfate_be gelusil_be acidic_be media_be whereas_be erythromycin_be basic_be media_be OTHER_DRUG neutral_af media_af ._af
25,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Lomefloxacin,sucralfate,mechanism,Moxifloxacin_bf DRUG reacts_be faster_be OTHER_DRUG gelusil_af acidic_af media_af whereas_af erythromycin_af basic_af media_af multi-minerals_af neutral_af media_af ._af
26,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Lomefloxacin,gelusil,mechanism,Moxifloxacin_bf DRUG reacts_be faster_be sucralfate_be OTHER_DRUG acidic_af media_af whereas_af erythromycin_af basic_af media_af multi-minerals_af neutral_af media_af ._af
27,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Lomefloxacin,erythromycin,mechanism,Moxifloxacin_bf DRUG reacts_be faster_be sucralfate_be gelusil_be acidic_be media_be whereas_be OTHER_DRUG basic_af media_af multi-minerals_af neutral_af media_af ._af
28,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Lomefloxacin,multi-minerals,mechanism,Moxifloxacin_bf DRUG reacts_be faster_be sucralfate_be gelusil_be acidic_be media_be whereas_be erythromycin_be basic_be media_be OTHER_DRUG neutral_af media_af ._af
44,"Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ",Ticlopidine,ketamine,mechanism,"DRUG treatment_be increased_be mean_be area_be plasma_be concentration-time_be curve_be extrapolated_be infinity_be (AUC(0-_be ))_be oral_be OTHER_DRUG 2_af ._af 4-fold_af ,_af whereas_af itraconazole_af treatment_af increase_af exposure_af S-ketamine_af ._af"
142,Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. ,Paroxetine,endoxifen,mechanism,DRUG fluoxetine_be reduce_be plasma_be concentration_be OTHER_DRUG 50%_af ._af
143,Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. ,fluoxetine,endoxifen,mechanism,Paroxetine_bf DRUG reduce_be plasma_be concentration_be OTHER_DRUG 50%_af ._af
175,"Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). ",midazolam,cyclosporine,mechanism,"Systemic_bf apparent_bf oral_bf DRUG clearance_be 24%_be (269_be 73_be vs_be ._be 354_be 102_be ml/min_be ,_be P_be =_be 0_be ._be 022)_be 31%_be (479_be 190_be vs_be ._be 688_be 265_be ml/min_be ,_be P_be =_be 0_be ._be 013)_be ,_be respectively_be ,_be lower_be cyclosporine-treated_be patients_be (n_be =_be 20)_be matched_be tacrolimus-treated_be patients_be (n_be =_be 20)_be ._be"
208,"Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. ",omeprazole,clopidogrel,mechanism,"Concomitant_bf use_bf DRUG OTHER_DRUG found_af decrease_af exposure_af (AUC)_af clopidogrel's_af active_af metabolite_af 50%_af sharply_af increase_af platelet_af reactivity_af ,_af result_af inhibition_af DRUG CYP2C19_af ,_af cytochrome_af P450_af (CYP)_af enzyme_af ._af"
211,Pantoprazole has a much weaker effect on clopidogrel's pharmacokinetics and on platelet reactivity during concomitant use. ,Pantoprazole,clopidogrel,mechanism,DRUG much_be weaker_be effect_be clopidogrel's_be pharmacokinetics_be platelet_be reactivity_be concomitant_be use_be ._be
231,Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. ,Calcium,nonheme iron,mechanism,DRUG known_be component_be diet_be may_be affect_be absorption_be nonheme_be heme_be iron_be ._be
232,Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. ,Calcium,heme iron,mechanism,DRUG known_be component_be diet_be may_be affect_be absorption_be nonheme_be heme_be iron_be ._be
234,"However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. ",calcium,iron,mechanism,"However_bf ,_bf evidence_bf DRUG effect_be OTHER_DRUG absorption_af mainly_af comes_af studies_af isolate_af effect_af DRUG dietary_af components_af ,_af detected_af single-meal_af studies_af ._af"
247,Calcium doses   1000 mg diminished nonheme iron absorption by an average of 49.6%.,Calcium,nonheme iron,mechanism,DRUG doses_be 1000_be mg_be diminished_be nonheme_be iron_be absorption_be average_be 49_be ._be 6%_be ._be
248,A calcium dose of 800 mg diminished absorption of 5 mg heme iron by 37.7%. ,calcium,heme iron,mechanism,A_bf DRUG dose_be 800_be mg_be diminished_be absorption_be 5_be mg_be heme_be iron_be 37_be ._be 7%_be ._be
249,"In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. ",calcium,nonheme iron,mechanism,"In_bf conclusion_bf ,_bf demonstrated_bf isolated_bf effect_bf DRUG (as_be chloride)_be absorption_be 5_be mg_be iron_be provided_be nonheme_be (as_be sulfate)_be heme_be (as_be CRBC)_be iron_be ._be"
250,"In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. ",calcium,heme iron,mechanism,"In_bf conclusion_bf ,_bf demonstrated_bf isolated_bf effect_bf DRUG (as_be chloride)_be absorption_be 5_be mg_be iron_be provided_be nonheme_be (as_be sulfate)_be heme_be (as_be CRBC)_be iron_be ._be"
402,Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. ,Ethanol,abacavir,mechanism,DRUG decreases_be elimination_be OTHER_DRUG causing_af increase_af overall_af exposure_af ._af The_af addition_af methadone_af clinically_af significant_af effect_af pharmacokinetic_af properties_af OTHER_DRUG ._af
408,"In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). ",methadone,ZIAGEN,mechanism,"In_bf study_bf 11_bf HIV-infected_bf patients_bf receiving_bf methadone-maintenance_bf therapy_bf (40_bf mg_bf 90_bf mg_bf daily)_bf 600_bf mg_bf OTHER_DRUG twice_be daily_be (twice_be currently_be recommended_be dose)_be ,_be oral_be DRUG clearance_af increased_af 22%_af (90%_af CI_af 6%_af 42%)_af ._af"
413,Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%. ,cholestyramine,ezetimibe,mechanism,Cholestyramine:_bf Concomitant_bf DRUG administration_be decreased_be mean_be AUC_be total_be OTHER_DRUG approximately_af 55%_af ._af
421,"Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. ",fenofibrate,ezetimibe,mechanism,"Fenofibrate:_bf In_bf pharmacokinetic_bf study_bf ,_bf concomitant_bf DRUG administration_be increased_be total_be OTHER_DRUG concentrations_af approximately_af 1_af ._af 5-fold_af ._af"
448,"Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. ",ezetimibe,cyclosporine,mechanism,"Cyclosporine:_bf The_bf total_bf DRUG level_be increased_be 12-fold_be one_be renal_be transplant_be patient_be receiving_be multiple_be medications_be ,_be including_be OTHER_DRUG ._af"
463,Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.,cimetidine,mebendazole,mechanism,Preliminary_bf evidence_bf suggests_bf DRUG inhibits_be OTHER_DRUG metabolism_af may_af result_af increase_af plasma_af concentrations_af OTHER_DRUG ._af
472,Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA. ,Aminoglutethimide,depo-subQ provera 104,mechanism,DRUG administered_be concomitantly_be depo-subQ_be provera_be 104_be may_be significantly_be decrease_be serum_be concentrations_be MPA_be ._be
478,A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. ,megestrol acetate,indinavir,mechanism,A_bf pharmacokinetic_bf study_bf demonstrated_bf coadministration_bf megestrol_bf acetate_bf OTHER_DRUG results_be significant_be decrease_be pharmacokinetic_be parameters_be (~36%_be Cmax_be ~28%_be AUC)_be OTHER_DRUG ._af
630,Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. ,aspirin,meloxicam,mechanism,Aspirin:_bf Concomitant_bf administration_bf DRUG (1000_be mg_be TID)_be healthy_be volunteers_be tended_be increase_be AUC_be (10%)_be Cmax_be (24%)_be OTHER_DRUG ._af
640,Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%. ,cholestyramine,meloxicam,mechanism,Cholestyramine:_bf Pretreatment_bf four_bf days_bf DRUG significantly_be increased_be clearance_be OTHER_DRUG 50%_af ._af
660,"Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. ",NSAIDs,lithium,mechanism,"Lithium:_bf In_bf clinical_bf trials_bf ,_bf DRUG produced_be elevation_be plasma_be OTHER_DRUG levels_af reduction_af renal_af OTHER_DRUG clearance_af ._af"
666,"In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. ",lithium,meloxicam,mechanism,"In_bf study_bf conducted_bf healthy_bf subjects_bf ,_bf mean_bf pre-dose_bf DRUG concentration_be AUC_be increased_be 21%_be subjects_be receiving_be DRUG doses_af ranging_af 804_af 1072_af mg_af BID_af OTHER_DRUG 15_af mg_af QD_af compared_af subjects_af receiving_af DRUG alone_af ._af"
801,"Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin; ",Anticholinergic agents,digoxin,mechanism,"Anticholinergic_bf agents_bf may_bf affect_bf gastrointestinal_bf absorption_bf various_bf drugs_bf ,_bf slowly_bf dissolving_bf dosage_bf forms_bf digoxin;_bf"
803,"Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided. ",antacids,anticholinergic agents,mechanism,"Because_bf DRUG may_be interfere_be absorption_be anticholinergic_be agents_be ,_be simultaneous_be use_be drugs_be avoided_be ._be"
854,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",methsuximide,phenytoin,mechanism,"Since_bf Celontin_bf (methsuximide)_bf may_bf interact_bf concurrently_bf administered_bf antiepileptic_bf drugs_bf ,_bf periodic_bf serum_bf level_bf determinations_bf drugs_bf may_bf necessary_bf (eg_bf DRUG may_be increase_be plasma_be concentrations_be OTHER_DRUG phenobarbital)_af ._af"
855,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",methsuximide,phenobarbital,mechanism,"Since_bf Celontin_bf (methsuximide)_bf may_bf interact_bf concurrently_bf administered_bf antiepileptic_bf drugs_bf ,_bf periodic_bf serum_bf level_bf determinations_bf drugs_bf may_bf necessary_bf (eg_bf DRUG may_be increase_be plasma_be concentrations_be phenytoin_be phenobarbital)_be ._be"
860,"Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity. ",Lithium,thiazides,mechanism,"DRUG renal_be clearance_be reduced_be OTHER_DRUG ,_af increasing_af risk_af DRUG toxicity_af ._af"
870,Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. ,methyldopa,ferrous sulfate,mechanism,Several_bf studies_bf demonstrate_bf decrease_bf bioavailability_bf DRUG ingested_be ferrous_be sulfate_be ferrous_be gluconate_be ._be
871,Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. ,methyldopa,ferrous gluconate,mechanism,Several_bf studies_bf demonstrate_bf decrease_bf bioavailability_bf DRUG ingested_be ferrous_be sulfate_be ferrous_be gluconate_be ._be
1015,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,coumarin anticoagulants,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1016,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,anticonvulsants,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be OTHER_DRUG (phenobarbital_af ,_af diphenylhydantoin_af ,_af primidone)_af ,_af phenylbutazone_af ,_af tricyclic_af drugs_af (imipramine_af ,_af clomipramine_af ,_af desipramine)_af ._af"
1017,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,phenobarbital,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1018,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,diphenylhydantoin,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be OTHER_DRUG ,_af primidone)_af ,_af phenylbutazone_af ,_af tricyclic_af drugs_af (imipramine_af ,_af clomipramine_af ,_af desipramine)_af ._af"
1019,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,primidone,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1020,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,phenylbutazone,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be OTHER_DRUG ,_af tricyclic_af drugs_af (imipramine_af ,_af clomipramine_af ,_af desipramine)_af ._af"
1021,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,tricyclic drugs,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1022,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,imipramine,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1023,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,clomipramine,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be OTHER_DRUG ,_af desipramine)_af ._af"
1024,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,desipramine,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1073,Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone; ,cyclosporin,methylprednisolone,mechanism,Mutual_bf inhibition_bf metabolism_bf occurs_bf concurrent_bf use_bf DRUG methylprednisolone;_be
1077,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenobarbital,methylprednisolone,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf DRUG ,_be phenytoin_be ,_be rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increased_af OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
1080,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenytoin,methylprednisolone,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf DRUG ,_be rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increased_af OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
1082,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",rifampin,methylprednisolone,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf phenytoin_bf ,_bf DRUG may_be increase_be clearance_be OTHER_DRUG may_af require_af increased_af OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
1086,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. ,troleandomycin,methylprednisolone,mechanism,Drugs_bf DRUG ketoconazole_be may_be inhibit_be metabolism_be OTHER_DRUG thus_af decrease_af clearance_af ._af
1087,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. ,ketoconazole,methylprednisolone,mechanism,Drugs_bf troleandomycin_bf DRUG may_be inhibit_be metabolism_be OTHER_DRUG thus_af decrease_af clearance_af ._af
1088,Methylprednisolone may increase the clearance of chronic high dose aspirin. ,Methylprednisolone,aspirin,mechanism,DRUG may_be increase_be clearance_be chronic_be high_be dose_be OTHER_DRUG ._af
1377,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",digoxin,metoclopramide,mechanism,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf OTHER_DRUG ,_be whereas_be rate_be and/or_be extent_be absorption_be drugs_be small_be bowel_be may_be increased_be (e_be ._be g_be ._be ,_be acetaminophen_be ,_be tetracycline_be ,_be levodopa_be ,_be ethanol_be ,_be cyclosporine)_be ._be"
1383,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",metoclopramide,acetaminophen,mechanism,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf DRUG ,_be whereas_be rate_be and/or_be extent_be absorption_be drugs_be small_be bowel_be may_be increased_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af tetracycline_af ,_af levodopa_af ,_af ethanol_af ,_af cyclosporine)_af ._af"
1405,The metabolism of Metopirone is accelerated by phenytoin; ,Metopirone,phenytoin,mechanism,The_bf metabolism_bf DRUG accelerated_be phenytoin;_be
1406,Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.,Metopirone,acetaminophen,mechanism,DRUG inhibits_be glucuronidation_be OTHER_DRUG could_af possibly_af potentiate_af OTHER_DRUG toxicity_af ._af
1416,"In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2. ",mexiletine,fluvoxamine,mechanism,"In_bf formal_bf ,_bf single-dose_bf interaction_bf study_bf (n_bf =_bf 6_bf males)_bf clearance_bf DRUG decreased_be 38%_be following_be coadministration_be OTHER_DRUG ,_af inhibitor_af CYP1A2_af ._af"
1431,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",phenytoin,Mexitil,mechanism,"When_bf DRUG hepatic_be enzyme_be inducers_be rifampin_be phenobarbital_be taken_be concurrently_be OTHER_DRUG ,_af lowered_af OTHER_DRUG plasma_af levels_af reported_af ._af"
1434,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",rifampin,Mexitil,mechanism,"When_bf phenytoin_bf hepatic_bf enzyme_bf inducers_bf DRUG phenobarbital_be taken_be concurrently_be OTHER_DRUG ,_af lowered_af OTHER_DRUG plasma_af levels_af reported_af ._af"
1436,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",phenobarbital,Mexitil,mechanism,"When_bf phenytoin_bf hepatic_bf enzyme_bf inducers_bf rifampin_bf DRUG taken_be concurrently_be OTHER_DRUG ,_af lowered_af OTHER_DRUG plasma_af levels_af reported_af ._af"
1446,"Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels; ",cimetidine,Mexitil,mechanism,"Concurrent_bf administration_bf DRUG OTHER_DRUG reported_af increase_af ,_af decrease_af ,_af leave_af unchanged_af OTHER_DRUG plasma_af levels;_af"
1457,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",magnesium-aluminum hydroxide,digoxin,mechanism,"Mexitil_bf alter_bf serum_bf OTHER_DRUG levels_be magnesium-aluminum_be hydroxide_be ,_be used_be treat_be gastrointestinal_be symptoms_be due_be Mexitil_be ,_be reported_be lower_be serum_be OTHER_DRUG levels_af ._af"
1459,Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels. ,Mexitil,theophylline,mechanism,Concurrent_bf use_bf DRUG OTHER_DRUG may_af lead_af increased_af plasma_af OTHER_DRUG levels_af ._af
1470,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Theophylline,Mexitil,mechanism,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf OTHER_DRUG ._be DRUG plasma_af levels_af returned_af pre-Mexitil_af values_af within_af 48_af hours_af discontinuing_af OTHER_DRUG ._af If_af OTHER_DRUG DRUG used_af concurrently_af ,_af DRUG blood_af levels_af monitored_af ,_af particularly_af OTHER_DRUG dose_af changed_af ._af"
1490,"Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of Mexitil   .",caffeine,Mexitil,mechanism,"Additionally_bf ,_bf one_bf controlled_bf study_bf five_bf normal_bf subjects_bf seven_bf patients_bf ,_bf clearance_bf DRUG decreased_be 50%_be following_be administration_be OTHER_DRUG ._af"
1491,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,terfenadine,mechanism,"DRUG inhibits_be liver's_be ability_be metabolize_be drugs_be -_be OTHER_DRUG ,_af astemizole_af ,_af cisapride_af ,_af cyclosporine_af ,_af tricyclic_af antidepressants_af ._af"
1492,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,astemizole,mechanism,"DRUG inhibits_be liver's_be ability_be metabolize_be drugs_be -_be terfenadine_be ,_be OTHER_DRUG ,_af cisapride_af ,_af cyclosporine_af ,_af tricyclic_af antidepressants_af ._af"
1493,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,cisapride,mechanism,"DRUG inhibits_be liver's_be ability_be metabolize_be drugs_be -_be terfenadine_be ,_be astemizole_be ,_be OTHER_DRUG ,_af cyclosporine_af ,_af tricyclic_af antidepressants_af ._af"
1494,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,cyclosporine,mechanism,"DRUG inhibits_be liver's_be ability_be metabolize_be drugs_be -_be terfenadine_be ,_be astemizole_be ,_be cisapride_be ,_be OTHER_DRUG ,_af tricyclic_af antidepressants_af ._af"
1495,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,tricyclic antidepressants,mechanism,"DRUG inhibits_be liver's_be ability_be metabolize_be drugs_be -_be terfenadine_be ,_be astemizole_be ,_be cisapride_be ,_be cyclosporine_be ,_be tricyclic_be antidepressants_be ._be"
1566,Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone. ,Sirolimus,MYCAMINE,mechanism,DRUG AUC_be increased_be 21%_be effect_be Cmax_be presence_be steady-state_be OTHER_DRUG compared_af DRUG alone_af ._af
1569,"Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone. ",Nifedipine,MYCAMINE,mechanism,"DRUG AUC_be Cmax_be increased_be 18%_be 42%_be ,_be respectively_be ,_be presence_be steady-state_be OTHER_DRUG compared_af DRUG alone_af ._af"
1608,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",erythromycin,midazolam,mechanism,"Drugs_bf DRUG ,_be diltiazem_be ,_be verapamil_be ,_be ketoconazole_be ,_be fluconazole_be itraconazole_be shown_be significantly_be increase_be C_be max_be AUC_be orally_be administered_be OTHER_DRUG ._af"
1613,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",diltiazem,midazolam,mechanism,"Drugs_bf erythromycin_bf ,_bf DRUG ,_be verapamil_be ,_be ketoconazole_be ,_be fluconazole_be itraconazole_be shown_be significantly_be increase_be C_be max_be AUC_be orally_be administered_be OTHER_DRUG ._af"
1617,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",verapamil,midazolam,mechanism,"Drugs_bf erythromycin_bf ,_bf diltiazem_bf ,_bf DRUG ,_be ketoconazole_be ,_be fluconazole_be itraconazole_be shown_be significantly_be increase_be C_be max_be AUC_be orally_be administered_be OTHER_DRUG ._af"
1620,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",ketoconazole,midazolam,mechanism,"Drugs_bf erythromycin_bf ,_bf diltiazem_bf ,_bf verapamil_bf ,_bf DRUG ,_be fluconazole_be itraconazole_be shown_be significantly_be increase_be C_be max_be AUC_be orally_be administered_be OTHER_DRUG ._af"
1622,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",fluconazole,midazolam,mechanism,"Drugs_bf erythromycin_bf ,_bf diltiazem_bf ,_bf verapamil_bf ,_bf ketoconazole_bf ,_bf DRUG itraconazole_be shown_be significantly_be increase_be C_be max_be AUC_be orally_be administered_be OTHER_DRUG ._af"
1623,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",itraconazole,midazolam,mechanism,"Drugs_bf erythromycin_bf ,_bf diltiazem_bf ,_bf verapamil_bf ,_bf ketoconazole_bf ,_bf fluconazole_bf DRUG shown_be significantly_be increase_be C_be max_be AUC_be orally_be administered_be OTHER_DRUG ._af"
1625,"Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. ",ritonavir,midazolam,mechanism,"Although_bf studied_bf ,_bf potent_bf cytochrome_bf P450_bf 3A4_bf inhibitors_bf DRUG nelfinavir_be may_be cause_be intense_be prolonged_be sedation_be respiratory_be depression_be due_be decrease_be plasma_be clearance_be OTHER_DRUG ._af"
1626,"Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. ",nelfinavir,midazolam,mechanism,"Although_bf studied_bf ,_bf potent_bf cytochrome_bf P450_bf 3A4_bf inhibitors_bf ritonavir_bf DRUG may_be cause_be intense_be prolonged_be sedation_be respiratory_be depression_be due_be decrease_be plasma_be clearance_be OTHER_DRUG ._af"
1629,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",rifampin,midazolam,mechanism,"Inducers_bf CYP3A4_bf Isozymes:_bf Cytochrome_bf P450_bf inducers_bf ,_bf DRUG ,_be carbamazepine_be ,_be phenytoin_be ,_be induce_be metabolism_be caused_be markedly_be decreased_be C_be max_be AUC_be oral_be OTHER_DRUG adult_af studies_af ._af"
1631,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",carbamazepine,midazolam,mechanism,"Inducers_bf CYP3A4_bf Isozymes:_bf Cytochrome_bf P450_bf inducers_bf ,_bf rifampin_bf ,_bf DRUG ,_be phenytoin_be ,_be induce_be metabolism_be caused_be markedly_be decreased_be C_be max_be AUC_be oral_be OTHER_DRUG adult_af studies_af ._af"
1632,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",phenytoin,midazolam,mechanism,"Inducers_bf CYP3A4_bf Isozymes:_bf Cytochrome_bf P450_bf inducers_bf ,_bf rifampin_bf ,_bf carbamazepine_bf ,_bf DRUG ,_be induce_be metabolism_be caused_be markedly_be decreased_be C_be max_be AUC_be oral_be OTHER_DRUG adult_af studies_af ._af"
1786,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,metformin,mechanism,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be OTHER_DRUG ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1787,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,cimetidine,mechanism,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be OTHER_DRUG ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1788,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,ranitidine,mechanism,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be OTHER_DRUG ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1789,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,procainamide,mechanism,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be OTHER_DRUG ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1790,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,triamterene,mechanism,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be OTHER_DRUG ,_af flecainide_af ,_af quinidine_af ._af"
1791,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,flecainide,mechanism,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
1792,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,quinidine,mechanism,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be flecainide_be ,_be OTHER_DRUG ._af"
1820,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",ketoconazole,mifepristone,mechanism,"Although_bf specific_bf drug_bf food_bf interactions_bf OTHER_DRUG studied_be ,_be basis_be drug_be metabolism_be CYP_be 3A4_be ,_be possible_be DRUG ,_af itraconazole_af ,_af erythromycin_af ,_af grapefruit_af juice_af may_af inhibit_af metabolism_af (increasing_af serum_af levels_af mifepristone)_af ._af"
1822,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",itraconazole,mifepristone,mechanism,"Although_bf specific_bf drug_bf food_bf interactions_bf OTHER_DRUG studied_be ,_be basis_be drug_be metabolism_be CYP_be 3A4_be ,_be possible_be ketoconazole_be ,_be DRUG ,_af erythromycin_af ,_af grapefruit_af juice_af may_af inhibit_af metabolism_af (increasing_af serum_af levels_af mifepristone)_af ._af"
1823,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",erythromycin,mifepristone,mechanism,"Although_bf specific_bf drug_bf food_bf interactions_bf OTHER_DRUG studied_be ,_be basis_be drug_be metabolism_be CYP_be 3A4_be ,_be possible_be ketoconazole_be ,_be itraconazole_be ,_be DRUG ,_af grapefruit_af juice_af may_af inhibit_af metabolism_af (increasing_af serum_af levels_af mifepristone)_af ._af"
1828,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",anticonvulsants,mifepristone,mechanism,"John_bf Wort_bf ,_bf certain_bf DRUG (phenytoin_be ,_be phenobarbital_be ,_be carbamazepine)_be may_be induce_be OTHER_DRUG metabolism_af (lowering_af serum_af levels_af mifepristone)_af ._af"
1832,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",phenytoin,mifepristone,mechanism,"John_bf Wort_bf ,_bf certain_bf anticonvulsants_bf (phenytoin_bf ,_bf phenobarbital_bf ,_bf carbamazepine)_bf may_bf induce_bf OTHER_DRUG metabolism_be (lowering_be serum_be levels_be mifepristone)_be ._be"
1835,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",phenobarbital,mifepristone,mechanism,"John_bf Wort_bf ,_bf certain_bf anticonvulsants_bf (phenytoin_bf ,_bf DRUG ,_be carbamazepine)_be may_be induce_be OTHER_DRUG metabolism_af (lowering_af serum_af levels_af mifepristone)_af ._af"
1837,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",carbamazepine,mifepristone,mechanism,"John_bf Wort_bf ,_bf certain_bf anticonvulsants_bf (phenytoin_bf ,_bf phenobarbital_bf ,_bf carbamazepine)_bf may_bf induce_bf OTHER_DRUG metabolism_be (lowering_be serum_be levels_be mifepristone)_be ._be"
1840,"While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. ",ZAVESCA,Cerezyme,mechanism,"While_bf co-administration_bf DRUG appeared_be increase_be clearance_be OTHER_DRUG 70%_af ,_af results_af conclusive_af small_af number_af subjects_af studied_af patients_af took_af variable_af doses_af OTHER_DRUG ._af"
1853,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",tetracyclines,aluminum,mechanism,"Absorption_bf DRUG impaired_be antacids_be containing_be OTHER_DRUG ,_af calcium_af magnesium_af ,_af iron-containing_af preparations_af ._af"
1854,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",tetracyclines,calcium,mechanism,"Absorption_bf DRUG impaired_be antacids_be containing_be aluminum_be ,_be OTHER_DRUG magnesium_af ,_af iron-containing_af preparations_af ._af"
1855,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",tetracyclines,magnesium,mechanism,"Absorption_bf DRUG impaired_be antacids_be containing_be aluminum_be ,_be calcium_be OTHER_DRUG ,_af iron-containing_af preparations_af ._af"
1856,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",tetracyclines,iron,mechanism,"Absorption_bf DRUG impaired_be antacids_be containing_be aluminum_be ,_be calcium_be magnesium_be ,_be iron-containing_be preparations_be ._be"
1881,Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects. ,alcohol,mirtazapine,mechanism,Alcohol:_bf Concomitant_bf administration_bf DRUG (equivalent_be 60_be g)_be minimal_be effect_be plasma_be levels_be OTHER_DRUG (15_af mg)_af 6_af healthy_af male_af subjects_af ._af
1892,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",diazepam,mirtazapine,mechanism,"Accordingly_bf ,_bf patients_bf advised_bf avoid_bf alcohol_bf taking_bf REMERON_bf SolTab_bf ._bf Diazepam:_bf Concomitant_bf administration_bf DRUG (15_be mg)_be minimal_be effect_be plasma_be levels_be OTHER_DRUG (15_af mg)_af 12_af healthy_af subjects_af ._af"
1895,"Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. ",Mitotane,warfarin,mechanism,"DRUG reported_be accelerate_be metabolism_be OTHER_DRUG mechanism_af hepatic_af microsomal_af enzyme_af induction_af ,_af leading_af increase_af dosage_af requirements_af OTHER_DRUG ._af"
2211,"However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.",ketoconazole,mometasone furoate,mechanism,"However_bf ,_bf DRUG ,_be potent_be inhibitor_be cytochrome_be P450_be 3A4_be ,_be may_be increase_be plasma_be levels_be mometasone_be furoate_be concomitant_be dosing_be ._be"
2344,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",Myfortic,magnesium,mechanism,"Antacids:_bf Absorption_bf single_bf dose_bf DRUG decreased_be administered_be 12_be stable_be renal_be transplant_be patients_be also_be taking_be magnesium-aluminum_be containing_be antacids_be (30_be mL):_be mean_be Cmax_be AUC(0-t)_be values_be MPA_be 25%_be 37%_be lower_be ,_be respectively_be ,_be DRUG administered_af alone_af fasting_af conditions_af ._af"
2345,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",Myfortic,aluminum,mechanism,"Antacids:_bf Absorption_bf single_bf dose_bf DRUG decreased_be administered_be 12_be stable_be renal_be transplant_be patients_be also_be taking_be magnesium-aluminum_be containing_be antacids_be (30_be mL):_be mean_be Cmax_be AUC(0-t)_be values_be MPA_be 25%_be 37%_be lower_be ,_be respectively_be ,_be DRUG administered_af alone_af fasting_af conditions_af ._af"
2397,"However, in a drug-drug interaction study, mean levonorgesterol AUC was decreased by 15% when coadministered with mycophenolate mofetil. ",levonorgesterol,mycophenolate mofetil,mechanism,"However_bf ,_bf drug-drug_bf interaction_bf study_bf ,_bf mean_bf DRUG AUC_be decreased_be 15%_be coadministered_be mycophenolate_be mofetil_be ._be"
2424,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",phenytoin,ondansetron,mechanism,"DRUG ,_be Carbamazepine_be ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be DRUG ,_af carbamazepine_af ,_af rifampicin)_af ,_af clearance_af OTHER_DRUG significantly_af increased_af OTHER_DRUG blood_af concentrations_af decreased_af ._af"
2425,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",phenytoin,ondansetron,mechanism,"DRUG ,_be Carbamazepine_be ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be DRUG ,_af carbamazepine_af ,_af rifampicin)_af ,_af clearance_af OTHER_DRUG significantly_af increased_af OTHER_DRUG blood_af concentrations_af decreased_af ._af"
2427,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",carbamazepine,ondansetron,mechanism,"Phenytoin_bf ,_bf DRUG ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be phenytoin_be ,_be DRUG ,_af rifampicin)_af ,_af clearance_af OTHER_DRUG significantly_af increased_af OTHER_DRUG blood_af concentrations_af decreased_af ._af"
2428,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",carbamazepine,ondansetron,mechanism,"Phenytoin_bf ,_bf DRUG ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be phenytoin_be ,_be DRUG ,_af rifampicin)_af ,_af clearance_af OTHER_DRUG significantly_af increased_af OTHER_DRUG blood_af concentrations_af decreased_af ._af"
2429,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",rifampicin,ondansetron,mechanism,"Phenytoin_bf ,_bf Carbamazepine_bf ,_bf Rifampicin:_bf In_bf patients_bf treated_bf potent_bf inducers_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf phenytoin_bf ,_bf carbamazepine_bf ,_bf rifampicin)_bf ,_bf clearance_bf OTHER_DRUG significantly_be increased_be OTHER_DRUG blood_af concentrations_af decreased_af ._af"
2430,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",rifampicin,ondansetron,mechanism,"Phenytoin_bf ,_bf Carbamazepine_bf ,_bf Rifampicin:_bf In_bf patients_bf treated_bf potent_bf inducers_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf phenytoin_bf ,_bf carbamazepine_bf ,_bf rifampicin)_bf ,_bf clearance_bf OTHER_DRUG significantly_be increased_be OTHER_DRUG blood_af concentrations_af decreased_af ._af"
2498,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,XENICAL,cyclosporine,mechanism,Cyclosporine:_bf Preliminary_bf data_bf DRUG OTHER_DRUG drug_af interaction_af study_af indicate_af reduction_af OTHER_DRUG plasma_af levels_af DRUG coadministered_af OTHER_DRUG ._af
2507,Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL. ,beta-carotene,XENICAL,mechanism,Fat-soluble_bf Vitamin_bf Supplements_bf Analogues:_bf A_bf pharmacokinetic_bf interaction_bf study_bf showed_bf 30%_bf reduction_bf DRUG supplement_be absorption_be concomitantly_be administered_be OTHER_DRUG ._af
2508,XENICAL inhibited absorption of a vitamin E acetate supplement by approximately 60%. ,XENICAL,vitamin E acetate,mechanism,DRUG inhibited_be absorption_be vitamin_be E_be acetate_be supplement_be approximately_be 60%_be ._be
2546,"Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",vitamin K,XENICAL,mechanism,"Therefore_bf ,_bf vitamin_bf K_bf absorption_bf may_bf decreased_bf OTHER_DRUG ,_be patients_be chronic_be stable_be doses_be warfarin_be prescribed_be OTHER_DRUG monitored_af closely_af changes_af coagulation_af parameters_af ._af"
2556,Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks. ,5-FU,ELOXATIN,mechanism,Increases_bf DRUG plasma_be concentrations_be approximately_be 20%_be observed_be doses_be 130_be mg/m2_be OTHER_DRUG dosed_af every_af 3_af weeks_af ._af
2564,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",oxandrolone,warfarin,mechanism,"Warfarin:_bf A_bf multidose_bf study_bf DRUG ,_be given_be 5_be 10_be mg_be BID_be 15_be healthy_be subjects_be concurrently_be treated_be OTHER_DRUG ,_af resulted_af mean_af increase_af S-warfarin_af half-life_af 26_af 48_af hours_af AUC_af 4_af ._af 55_af 12_af ._af 08_af ng*hr/mL:_af similar_af increases_af R-warfarin_af half-life_af AUC_af also_af detected_af ._af"
2577,Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. ,Oxandrolone,hypoglycemic agents,mechanism,Oral_bf hypoglycemic_bf agents_bf DRUG may_be inhibit_be metabolism_be oral_be hypoglycemic_be agents_be ._be
2587,"Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor. ",DITROPAN XL,ketoconazole,mechanism,"Mean_bf oxybutynin_bf chloride_bf plasma_bf concentrations_bf approximately_bf 2_bf fold_bf higher_bf DITROPAN_bf XL_bf administered_bf OTHER_DRUG ,_be potent_be CYP3A4_be inhibitor_be ._be"
2593,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",antimycotic agents,oxybutynin,mechanism,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf clarithromycin)_bf ,_bf may_bf alter_bf OTHER_DRUG mean_be pharmacokinetic_be parameters_be (i_be ._be ._be ,_be Cmax_be AUC)_be ._be"
2598,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",itraconazole,oxybutynin,mechanism,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf DRUG miconazole)_be macrolide_be antibiotics_be (e_be ._be g_be ._be ,_be erythromycin_be clarithromycin)_be ,_be may_be alter_be OTHER_DRUG mean_af pharmacokinetic_af parameters_af (i_af ._af ._af ,_af Cmax_af AUC)_af ._af"
2602,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",miconazole,oxybutynin,mechanism,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf clarithromycin)_bf ,_bf may_bf alter_bf OTHER_DRUG mean_be pharmacokinetic_be parameters_be (i_be ._be ._be ,_be Cmax_be AUC)_be ._be"
2605,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",macrolide antibiotics,oxybutynin,mechanism,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf clarithromycin)_bf ,_bf may_bf alter_bf OTHER_DRUG mean_be pharmacokinetic_be parameters_be (i_be ._be ._be ,_be Cmax_be AUC)_be ._be"
2607,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",erythromycin,oxybutynin,mechanism,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG clarithromycin)_be ,_be may_be alter_be OTHER_DRUG mean_af pharmacokinetic_af parameters_af (i_af ._af ._af ,_af Cmax_af AUC)_af ._af"
2608,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",clarithromycin,oxybutynin,mechanism,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf clarithromycin)_bf ,_bf may_bf alter_bf OTHER_DRUG mean_be pharmacokinetic_be parameters_be (i_be ._be ._be ,_be Cmax_be AUC)_be ._be"
2995,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",pantoprazole,ketoconazole,mechanism,"Because_bf profound_bf long_bf lasting_bf inhibition_bf gastric_bf acid_bf secretion_bf ,_bf DRUG may_be interfere_be absorption_be drugs_be gastric_be pH_be important_be determinant_be bioavailability_be (eg_be ,_be OTHER_DRUG ,_af ampicillin_af esters_af ,_af iron_af salts)_af ._af"
2996,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",pantoprazole,ampicillin,mechanism,"Because_bf profound_bf long_bf lasting_bf inhibition_bf gastric_bf acid_bf secretion_bf ,_bf DRUG may_be interfere_be absorption_be drugs_be gastric_be pH_be important_be determinant_be bioavailability_be (eg_be ,_be ketoconazole_be ,_be OTHER_DRUG esters_af ,_af iron_af salts)_af ._af"
2997,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",pantoprazole,iron,mechanism,"Because_bf profound_bf long_bf lasting_bf inhibition_bf gastric_bf acid_bf secretion_bf ,_bf DRUG may_be interfere_be absorption_be drugs_be gastric_be pH_be important_be determinant_be bioavailability_be (eg_be ,_be ketoconazole_be ,_be ampicillin_be esters_be ,_be OTHER_DRUG salts)_af ._af"
3007,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,paricalcitol,mechanism,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be OTHER_DRUG AUC0-_af ._af Since_af OTHER_DRUG partially_af metabolized_af CYP3A_af DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af OTHER_DRUG DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3128,"Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.",fat-soluble vitamins,cholestyramine,mechanism,"Drugs_bf impair_bf intestinal_bf absorption_bf fat-soluble_bf vitamins_bf ,_bf OTHER_DRUG ,_be may_be interfere_be absorption_be Zemplar_be Capsules_be ._be"
3130,"Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.",cholestyramine,Zemplar,mechanism,"Drugs_bf impair_bf intestinal_bf absorption_bf fat-soluble_bf vitamins_bf ,_bf DRUG ,_be may_be interfere_be absorption_be OTHER_DRUG Capsules_af ._af"
3135,"In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. ",opioids,pegvisomant,mechanism,"In_bf clinical_bf studies_bf ,_bf patients_bf DRUG often_be needed_be higher_be serum_be OTHER_DRUG concentrations_af achieve_af appropriate_af IGF-I_af suppression_af compared_af patients_af receiving_af DRUG ._af"
3146,Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. ,TRENTAL,theophylline,mechanism,Concomitant_bf administration_bf DRUG theophylline-containing_be drugs_be leads_be increased_be OTHER_DRUG levels_af OTHER_DRUG toxicity_af individuals_af ._af
3259,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",digoxin,perindopril,mechanism,"Digoxin:_bf A_bf controlled_bf pharmacokinetic_bf study_bf shown_bf effect_bf plasma_bf DRUG concentrations_be coadministered_be ACEON_be Tablets_be ,_be effect_be DRUG plasma_af concentration_af perindopril/perindoprilat_af excluded_af ._af"
3260,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",digoxin,perindoprilat,mechanism,"Digoxin:_bf A_bf controlled_bf pharmacokinetic_bf study_bf shown_bf effect_bf plasma_bf DRUG concentrations_be coadministered_be ACEON_be Tablets_be ,_be effect_be DRUG plasma_af concentration_af perindopril/perindoprilat_af excluded_af ._af"
3379,Pindolol has been shown to increase serum thioridazine levels when both drugs are co-administered. ,Pindolol,thioridazine,mechanism,DRUG shown_be increase_be serum_be OTHER_DRUG levels_af drugs_af co-administered_af ._af
3398,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",FELDENE,aspirin,mechanism,"Plasma_bf levels_bf piroxicam_bf depressed_bf approximately_bf 80%_bf normal_bf values_bf DRUG administered_be conjunction_be OTHER_DRUG (3900_af mg/day)_af ,_af concomitant_af administration_af antacids_af effect_af piroxicam_af plasma_af levels_af ._af Nonsteroidal_af anti-inflammatory_af agents_af ,_af including_af DRUG ,_af reported_af increase_af steady_af state_af plasma_af lithium_af levels_af ._af"
3417,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",Nonsteroidal anti-inflammatory agents,lithium,mechanism,"Plasma_bf levels_bf piroxicam_bf depressed_bf approximately_bf 80%_bf normal_bf values_bf FELDENE_bf administered_bf conjunction_bf aspirin_bf (3900_bf mg/day)_bf ,_bf concomitant_bf administration_bf antacids_bf effect_bf piroxicam_bf plasma_bf levels_bf ._bf Nonsteroidal_bf anti-inflammatory_bf agents_bf ,_bf including_bf FELDENE_bf ,_bf reported_bf increase_bf steady_bf state_bf plasma_bf OTHER_DRUG levels_be ._be"
3418,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",FELDENE,lithium,mechanism,"Plasma_bf levels_bf piroxicam_bf depressed_bf approximately_bf 80%_bf normal_bf values_bf DRUG administered_be conjunction_be aspirin_be (3900_be mg/day)_be ,_be concomitant_be administration_be antacids_be effect_be piroxicam_be plasma_be levels_be ._be Nonsteroidal_be anti-inflammatory_be agents_be ,_be including_be DRUG ,_af reported_af increase_af steady_af state_af plasma_af OTHER_DRUG levels_af ._af"
3460,"Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). ",Cimetidine,pramipexole,mechanism,"Cimetidine:_bf DRUG ,_be known_be inhibitor_be renal_be tubular_be secretion_be organic_be bases_be via_be cationic_be transport_be system_be ,_be caused_be 50%_be increase_be OTHER_DRUG AUC_af 40%_af increase_af half-life_af (N=_af 12)_af ._af"
3470,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cimetidine,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be ranitidine_be ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3482,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",ranitidine,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf DRUG ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3493,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",diltiazem,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf DRUG ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3503,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",triamterene,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf DRUG ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3512,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",verapamil,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf DRUG ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3520,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinidine,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf DRUG ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3527,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinine,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf OTHER_DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be OTHER_DRUG ._af"
3544,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cephalosporins,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf OTHER_DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be DRUG ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3548,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",penicillins,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf OTHER_DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be DRUG ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3551,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",indomethacin,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf OTHER_DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be DRUG ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3553,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",hydrochlorothiazide,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf OTHER_DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be DRUG ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3554,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",chlorpropamide,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf OTHER_DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be OTHER_DRUG ._af"
3603,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenobarbital,corticosteroids,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf DRUG ,_be phenytoin_be rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increases_af corticosteroid_af dose_af achieve_af desired_af response_af ._af"
3604,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenobarbital,corticosteroid,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf DRUG ,_be phenytoin_be rifampin_be may_be increase_be clearance_be corticosteroids_be may_be require_be increases_be OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
3606,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenytoin,corticosteroids,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf DRUG rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increases_af corticosteroid_af dose_af achieve_af desired_af response_af ._af"
3607,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenytoin,corticosteroid,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf DRUG rifampin_be may_be increase_be clearance_be corticosteroids_be may_be require_be increases_be OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
3608,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",rifampin,corticosteroids,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf phenytoin_bf DRUG may_be increase_be clearance_be OTHER_DRUG may_af require_af increases_af corticosteroid_af dose_af achieve_af desired_af response_af ._af"
3609,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",rifampin,corticosteroid,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf phenytoin_bf DRUG may_be increase_be clearance_be corticosteroids_be may_be require_be increases_be OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
3612,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. ,troleandomycin,corticosteroids,mechanism,Drugs_bf DRUG ketoconazole_be may_be inhibit_be metabolism_be OTHER_DRUG thus_af decrease_af clearance_af ._af
3613,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. ,ketoconazole,corticosteroids,mechanism,Drugs_bf troleandomycin_bf DRUG may_be inhibit_be metabolism_be OTHER_DRUG thus_af decrease_af clearance_af ._af
3614,Corticosteroids may increase the clearance of chronic high dose aspirin. ,Corticosteroids,aspirin,mechanism,DRUG may_be increase_be clearance_be chronic_be high_be dose_be OTHER_DRUG ._af
12,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",fluoroquinolones,multi minerals,No interaction,"Being_bf moxifloxacin_bf lomefloxacin_bf DRUG interaction_be study_be carried_be sucralfate_be ,_be gelusil_be ,_be erythromycin_be multi_be minerals_be ._be"
13,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",sucralfate,gelusil,No interaction,"Being_bf moxifloxacin_bf lomefloxacin_bf fluoroquinolones_bf interaction_bf study_bf carried_bf DRUG ,_be OTHER_DRUG ,_af erythromycin_af multi_af minerals_af ._af"
14,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",sucralfate,erythromycin,No interaction,"Being_bf moxifloxacin_bf lomefloxacin_bf fluoroquinolones_bf interaction_bf study_bf carried_bf DRUG ,_be gelusil_be ,_be OTHER_DRUG multi_af minerals_af ._af"
15,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",sucralfate,multi minerals,No interaction,"Being_bf moxifloxacin_bf lomefloxacin_bf fluoroquinolones_bf interaction_bf study_bf carried_bf DRUG ,_be gelusil_be ,_be erythromycin_be multi_be minerals_be ._be"
16,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",gelusil,erythromycin,No interaction,"Being_bf moxifloxacin_bf lomefloxacin_bf fluoroquinolones_bf interaction_bf study_bf carried_bf sucralfate_bf ,_bf DRUG ,_be OTHER_DRUG multi_af minerals_af ._af"
17,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",gelusil,multi minerals,No interaction,"Being_bf moxifloxacin_bf lomefloxacin_bf fluoroquinolones_bf interaction_bf study_bf carried_bf sucralfate_bf ,_bf DRUG ,_be erythromycin_be multi_be minerals_be ._be"
18,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",erythromycin,multi minerals,No interaction,"Being_bf moxifloxacin_bf lomefloxacin_bf fluoroquinolones_bf interaction_bf study_bf carried_bf sucralfate_bf ,_bf gelusil_bf ,_bf DRUG multi_be minerals_be ._be"
19,The response of moxifloxacin and lomefloxacin after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector. ,moxifloxacin,lomefloxacin,No interaction,The_bf response_bf DRUG OTHER_DRUG interaction_af co-administered_af drugs_af different_af conditions_af temperature_af noted_af using_af Shimadzu_af HPLC_af system_af PDA_af detector_af ._af
20,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Moxifloxacin,Lomefloxacin,No interaction,DRUG OTHER_DRUG reacts_af faster_af sucralfate_af gelusil_af acidic_af media_af whereas_af erythromycin_af basic_af media_af multi-minerals_af neutral_af media_af ._af
29,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,sucralfate,gelusil,No interaction,Moxifloxacin_bf Lomefloxacin_bf reacts_bf faster_bf DRUG OTHER_DRUG acidic_af media_af whereas_af erythromycin_af basic_af media_af multi-minerals_af neutral_af media_af ._af
30,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,sucralfate,erythromycin,No interaction,Moxifloxacin_bf Lomefloxacin_bf reacts_bf faster_bf DRUG gelusil_be acidic_be media_be whereas_be OTHER_DRUG basic_af media_af multi-minerals_af neutral_af media_af ._af
31,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,sucralfate,multi-minerals,No interaction,Moxifloxacin_bf Lomefloxacin_bf reacts_bf faster_bf DRUG gelusil_be acidic_be media_be whereas_be erythromycin_be basic_be media_be OTHER_DRUG neutral_af media_af ._af
32,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,gelusil,erythromycin,No interaction,Moxifloxacin_bf Lomefloxacin_bf reacts_bf faster_bf sucralfate_bf DRUG acidic_be media_be whereas_be OTHER_DRUG basic_af media_af multi-minerals_af neutral_af media_af ._af
33,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,gelusil,multi-minerals,No interaction,Moxifloxacin_bf Lomefloxacin_bf reacts_bf faster_bf sucralfate_bf DRUG acidic_be media_be whereas_be erythromycin_be basic_be media_be OTHER_DRUG neutral_af media_af ._af
34,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,erythromycin,multi-minerals,No interaction,Moxifloxacin_bf Lomefloxacin_bf reacts_bf faster_bf sucralfate_bf gelusil_bf acidic_bf media_bf whereas_bf DRUG basic_be media_be OTHER_DRUG neutral_af media_af ._af
35,"Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
",S-ketamine,itraconazole,No interaction,Exposure_bf oral_bf DRUG unaffected_be OTHER_DRUG greatly_af increased_af ticlopidine_af ._af
37,"Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
",itraconazole,ticlopidine,No interaction,Exposure_bf oral_bf S-ketamine_bf unaffected_bf DRUG greatly_be increased_be OTHER_DRUG ._af
38,This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. ,S-ketamine,ticlopidine,No interaction,This_bf study_bf examined_bf drug-drug_bf interactions_bf oral_bf DRUG cytochrome_be P450_be (CYP)_be 2B6_be inhibitor_be OTHER_DRUG CYP3A_af inhibitor_af itraconazole_af ._af
39,This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. ,S-ketamine,itraconazole,No interaction,This_bf study_bf examined_bf drug-drug_bf interactions_bf oral_bf DRUG cytochrome_be P450_be (CYP)_be 2B6_be inhibitor_be ticlopidine_be CYP3A_be inhibitor_be OTHER_DRUG ._af
40,This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. ,ticlopidine,itraconazole,No interaction,This_bf study_bf examined_bf drug-drug_bf interactions_bf oral_bf S-ketamine_bf cytochrome_bf P450_bf (CYP)_bf 2B6_bf inhibitor_bf DRUG CYP3A_be inhibitor_be OTHER_DRUG ._af
41,"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ",S-ketamine,ticlopidine,No interaction,"In_bf randomized_bf ,_bf blinded_bf ,_bf crossover_bf study_bf ,_bf 11_bf healthy_bf volunteers_bf ingested_bf 0_bf ._bf 2_bf mg/kg_bf DRUG pretreatments_be oral_be OTHER_DRUG (250_af mg_af twice_af daily)_af ,_af itraconazole_af (200_af mg_af daily)_af ,_af placebo_af 6-day_af treatment_af periods_af intervals_af 4_af weeks_af ._af"
42,"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ",S-ketamine,itraconazole,No interaction,"In_bf randomized_bf ,_bf blinded_bf ,_bf crossover_bf study_bf ,_bf 11_bf healthy_bf volunteers_bf ingested_bf 0_bf ._bf 2_bf mg/kg_bf DRUG pretreatments_be oral_be ticlopidine_be (250_be mg_be twice_be daily)_be ,_be OTHER_DRUG (200_af mg_af daily)_af ,_af placebo_af 6-day_af treatment_af periods_af intervals_af 4_af weeks_af ._af"
43,"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ",ticlopidine,itraconazole,No interaction,"In_bf randomized_bf ,_bf blinded_bf ,_bf crossover_bf study_bf ,_bf 11_bf healthy_bf volunteers_bf ingested_bf 0_bf ._bf 2_bf mg/kg_bf S-ketamine_bf pretreatments_bf oral_bf DRUG (250_be mg_be twice_be daily)_be ,_be OTHER_DRUG (200_af mg_af daily)_af ,_af placebo_af 6-day_af treatment_af periods_af intervals_af 4_af weeks_af ._af"
45,"Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ",Ticlopidine,itraconazole,No interaction,"DRUG treatment_be increased_be mean_be area_be plasma_be concentration-time_be curve_be extrapolated_be infinity_be (AUC(0-_be ))_be oral_be ketamine_be 2_be ._be 4-fold_be ,_be whereas_be OTHER_DRUG treatment_af increase_af exposure_af S-ketamine_af ._af"
46,"Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ",Ticlopidine,S-ketamine,No interaction,"DRUG treatment_be increased_be mean_be area_be plasma_be concentration-time_be curve_be extrapolated_be infinity_be (AUC(0-_be ))_be oral_be ketamine_be 2_be ._be 4-fold_be ,_be whereas_be itraconazole_be treatment_be increase_be exposure_be OTHER_DRUG ._af"
47,"Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ",ketamine,itraconazole,No interaction,"Ticlopidine_bf treatment_bf increased_bf mean_bf area_bf plasma_bf concentration-time_bf curve_bf extrapolated_bf infinity_bf (AUC(0-_bf ))_bf oral_bf DRUG 2_be ._be 4-fold_be ,_be whereas_be OTHER_DRUG treatment_af increase_af exposure_af S-ketamine_af ._af"
48,"Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ",ketamine,S-ketamine,No interaction,"Ticlopidine_bf treatment_bf increased_bf mean_bf area_bf plasma_bf concentration-time_bf curve_bf extrapolated_bf infinity_bf (AUC(0-_bf ))_bf oral_bf DRUG 2_be ._be 4-fold_be ,_be whereas_be itraconazole_be treatment_be increase_be exposure_be OTHER_DRUG ._af"
49,"Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ",itraconazole,S-ketamine,No interaction,"Ticlopidine_bf treatment_bf increased_bf mean_bf area_bf plasma_bf concentration-time_bf curve_bf extrapolated_bf infinity_bf (AUC(0-_bf ))_bf oral_bf ketamine_bf 2_bf ._bf 4-fold_bf ,_bf whereas_bf DRUG treatment_be increase_be exposure_be OTHER_DRUG ._af"
50,The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ,norketamine,ketamine,No interaction,The_bf ratio_bf DRUG AUC(0-_be )_be OTHER_DRUG AUC(0-_af )_af significantly_af decreased_af ticlopidine_af (P_af &lt;_af 0_af ._af 001)_af itraconazole_af phases_af (P_af =_af 0_af ._af 006)_af compared_af placebo_af ._af
51,The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ,norketamine,ticlopidine,No interaction,The_bf ratio_bf DRUG AUC(0-_be )_be ketamine_be AUC(0-_be )_be significantly_be decreased_be OTHER_DRUG (P_af &lt;_af 0_af ._af 001)_af itraconazole_af phases_af (P_af =_af 0_af ._af 006)_af compared_af placebo_af ._af
52,The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ,norketamine,itraconazole,No interaction,The_bf ratio_bf DRUG AUC(0-_be )_be ketamine_be AUC(0-_be )_be significantly_be decreased_be ticlopidine_be (P_be &lt;_be 0_be ._be 001)_be OTHER_DRUG phases_af (P_af =_af 0_af ._af 006)_af compared_af placebo_af ._af
53,The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ,ketamine,ticlopidine,No interaction,The_bf ratio_bf norketamine_bf AUC(0-_bf )_bf DRUG AUC(0-_be )_be significantly_be decreased_be OTHER_DRUG (P_af &lt;_af 0_af ._af 001)_af itraconazole_af phases_af (P_af =_af 0_af ._af 006)_af compared_af placebo_af ._af
54,The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ,ketamine,itraconazole,No interaction,The_bf ratio_bf norketamine_bf AUC(0-_bf )_bf DRUG AUC(0-_be )_be significantly_be decreased_be ticlopidine_be (P_be &lt;_be 0_be ._be 001)_be OTHER_DRUG phases_af (P_af =_af 0_af ._af 006)_af compared_af placebo_af ._af
55,The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ,ticlopidine,itraconazole,No interaction,The_bf ratio_bf norketamine_bf AUC(0-_bf )_bf ketamine_bf AUC(0-_bf )_bf significantly_bf decreased_bf DRUG (P_be &lt;_be 0_be ._be 001)_be OTHER_DRUG phases_af (P_af =_af 0_af ._af 006)_af compared_af placebo_af ._af
56,"In the ticlopidine and itraconazole phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05). ",ticlopidine,itraconazole,No interaction,"In_bf DRUG OTHER_DRUG phases_af ,_af areas_af effect-time_af curves_af (self-reported_af drowsiness_af performance)_af significantly_af higher_af placebo_af phase_af (P_af <_af 0_af ._af 05)_af ._af"
58,"The 3-Deazaneplanocin A (DZNep), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia. ",3-Deazaneplanocin A,DZNep,No interaction,"The_bf 3-Deazaneplanocin_bf A_bf (DZNep)_bf ,_bf one_bf S-adenosylhomocysteine_bf (AdoHcy)_bf hydrolase_bf inhibitors_bf ,_bf shown_bf antitumor_bf activities_bf broad_bf range_bf solid_bf tumors_bf acute_bf myeloid_bf leukemia_bf ._bf"
59,"We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ",DZNep,DZNep,No interaction,"We_bf also_bf found_bf Bcl-2_bf overexpressed_bf DRUG insensitive_be cells_be ,_be cotreatment_be DRUG ABT-737_af ,_af Bcl-2_af family_af inhibitor_af ,_af synergistically_af inhibited_af growth_af induced_af apoptosis_af DRUG insensitive_af MM_af cells_af ._af"
60,"We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ",DZNep,ABT-737,No interaction,"We_bf also_bf found_bf Bcl-2_bf overexpressed_bf DRUG insensitive_be cells_be ,_be cotreatment_be DRUG OTHER_DRUG ,_af Bcl-2_af family_af inhibitor_af ,_af synergistically_af inhibited_af growth_af induced_af apoptosis_af DRUG insensitive_af MM_af cells_af ._af"
61,"We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ",DZNep,DZNep,No interaction,"We_bf also_bf found_bf Bcl-2_bf overexpressed_bf DRUG insensitive_be cells_be ,_be cotreatment_be DRUG ABT-737_af ,_af Bcl-2_af family_af inhibitor_af ,_af synergistically_af inhibited_af growth_af induced_af apoptosis_af DRUG insensitive_af MM_af cells_af ._af"
63,"We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ",DZNep,DZNep,No interaction,"We_bf also_bf found_bf Bcl-2_bf overexpressed_bf DRUG insensitive_be cells_be ,_be cotreatment_be DRUG ABT-737_af ,_af Bcl-2_af family_af inhibitor_af ,_af synergistically_af inhibited_af growth_af induced_af apoptosis_af DRUG insensitive_af MM_af cells_af ._af"
64,"We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ",ABT-737,DZNep,No interaction,"We_bf also_bf found_bf Bcl-2_bf overexpressed_bf OTHER_DRUG insensitive_be cells_be ,_be cotreatment_be OTHER_DRUG DRUG ,_af Bcl-2_af family_af inhibitor_af ,_af synergistically_af inhibited_af growth_af induced_af apoptosis_af OTHER_DRUG insensitive_af MM_af cells_af ._af"
65,"In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. ",DZNep,ABT-737,No interaction,"In_bf addition_bf ,_bf DRUG insensitivity_be might_be associated_be overexpression_be Bcl-2_be ,_be combination_be OTHER_DRUG DRUG could_af synergistically_af induced_af apoptosis_af ._af"
66,"In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. ",DZNep,DZNep,No interaction,"In_bf addition_bf ,_bf DRUG insensitivity_be might_be associated_be overexpression_be Bcl-2_be ,_be combination_be ABT-737_be DRUG could_af synergistically_af induced_af apoptosis_af ._af"
70,"Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study.
",Antidepressant,warfarin,No interaction,Antidepressant-warfarin_bf interaction_bf associated_bf gastrointestinal_bf bleeding_bf risk_bf case-control_bf study_bf ._bf
71,We sought to evaluate whether initiation of an antidepressant increases the risk of hospitalization for gastrointestinal bleeding in warfarin users.,antidepressant,warfarin,No interaction,We_bf sought_bf evaluate_bf whether_bf initiation_bf DRUG increases_be risk_be hospitalization_be gastrointestinal_be bleeding_be OTHER_DRUG users_af ._af
72,"In total, 430,455 warfarin users contributed 407,370 person-years of warfarin use. ",warfarin,warfarin,No interaction,"In_bf total_bf ,_bf 430_bf ,_bf 455_bf DRUG users_be contributed_be 407_be ,_be 370_be person-years_be DRUG use_af ._af"
77,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",citalopram,fluoxetine,No interaction,"Warfarin_bf users_bf increased_bf odds_bf ratio_bf gastrointestinal_bf bleeding_bf upon_bf initiation_bf DRUG (OR_be =_be 1_be ._be 73_be [95%_be CI_be ,_be 1_be ._be 25-2_be ._be 38])_be ,_be OTHER_DRUG (OR_af =_af 1_af ._af 63_af [95%_af CI_af ,_af 1_af ._af 11-2_af ._af 38])_af ,_af paroxetine_af (OR_af =_af 1_af ._af 64_af [95%_af CI_af ,_af 1_af ._af 27-2_af ._af 12])_af ,_af amitriptyline_af (OR_af =_af 1_af ._af 47_af [95%_af CI_af ,_af 1_af ._af 02-2_af ._af 11])_af ._af"
78,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",citalopram,paroxetine,No interaction,"Warfarin_bf users_bf increased_bf odds_bf ratio_bf gastrointestinal_bf bleeding_bf upon_bf initiation_bf DRUG (OR_be =_be 1_be ._be 73_be [95%_be CI_be ,_be 1_be ._be 25-2_be ._be 38])_be ,_be fluoxetine_be (OR_be =_be 1_be ._be 63_be [95%_be CI_be ,_be 1_be ._be 11-2_be ._be 38])_be ,_be OTHER_DRUG (OR_af =_af 1_af ._af 64_af [95%_af CI_af ,_af 1_af ._af 27-2_af ._af 12])_af ,_af amitriptyline_af (OR_af =_af 1_af ._af 47_af [95%_af CI_af ,_af 1_af ._af 02-2_af ._af 11])_af ._af"
79,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",citalopram,amitriptyline,No interaction,"Warfarin_bf users_bf increased_bf odds_bf ratio_bf gastrointestinal_bf bleeding_bf upon_bf initiation_bf DRUG (OR_be =_be 1_be ._be 73_be [95%_be CI_be ,_be 1_be ._be 25-2_be ._be 38])_be ,_be fluoxetine_be (OR_be =_be 1_be ._be 63_be [95%_be CI_be ,_be 1_be ._be 11-2_be ._be 38])_be ,_be paroxetine_be (OR_be =_be 1_be ._be 64_be [95%_be CI_be ,_be 1_be ._be 27-2_be ._be 12])_be ,_be OTHER_DRUG (OR_af =_af 1_af ._af 47_af [95%_af CI_af ,_af 1_af ._af 02-2_af ._af 11])_af ._af"
80,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",fluoxetine,paroxetine,No interaction,"Warfarin_bf users_bf increased_bf odds_bf ratio_bf gastrointestinal_bf bleeding_bf upon_bf initiation_bf citalopram_bf (OR_bf =_bf 1_bf ._bf 73_bf [95%_bf CI_bf ,_bf 1_bf ._bf 25-2_bf ._bf 38])_bf ,_bf DRUG (OR_be =_be 1_be ._be 63_be [95%_be CI_be ,_be 1_be ._be 11-2_be ._be 38])_be ,_be OTHER_DRUG (OR_af =_af 1_af ._af 64_af [95%_af CI_af ,_af 1_af ._af 27-2_af ._af 12])_af ,_af amitriptyline_af (OR_af =_af 1_af ._af 47_af [95%_af CI_af ,_af 1_af ._af 02-2_af ._af 11])_af ._af"
81,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",fluoxetine,amitriptyline,No interaction,"Warfarin_bf users_bf increased_bf odds_bf ratio_bf gastrointestinal_bf bleeding_bf upon_bf initiation_bf citalopram_bf (OR_bf =_bf 1_bf ._bf 73_bf [95%_bf CI_bf ,_bf 1_bf ._bf 25-2_bf ._bf 38])_bf ,_bf DRUG (OR_be =_be 1_be ._be 63_be [95%_be CI_be ,_be 1_be ._be 11-2_be ._be 38])_be ,_be paroxetine_be (OR_be =_be 1_be ._be 64_be [95%_be CI_be ,_be 1_be ._be 27-2_be ._be 12])_be ,_be OTHER_DRUG (OR_af =_af 1_af ._af 47_af [95%_af CI_af ,_af 1_af ._af 02-2_af ._af 11])_af ._af"
82,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",paroxetine,amitriptyline,No interaction,"Warfarin_bf users_bf increased_bf odds_bf ratio_bf gastrointestinal_bf bleeding_bf upon_bf initiation_bf citalopram_bf (OR_bf =_bf 1_bf ._bf 73_bf [95%_bf CI_bf ,_bf 1_bf ._bf 25-2_bf ._bf 38])_bf ,_bf fluoxetine_bf (OR_bf =_bf 1_bf ._bf 63_bf [95%_bf CI_bf ,_bf 1_bf ._bf 11-2_bf ._bf 38])_bf ,_bf DRUG (OR_be =_be 1_be ._be 64_be [95%_be CI_be ,_be 1_be ._be 27-2_be ._be 12])_be ,_be OTHER_DRUG (OR_af =_af 1_af ._af 47_af [95%_af CI_af ,_af 1_af ._af 02-2_af ._af 11])_af ._af"
89,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",citalopram,fluoxetine,No interaction,"Warfarin_bf users_bf initiated_bf DRUG ,_be OTHER_DRUG ,_af paroxetine_af ,_af amitriptyline_af ,_af mirtazapine_af increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
90,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",citalopram,paroxetine,No interaction,"Warfarin_bf users_bf initiated_bf DRUG ,_be fluoxetine_be ,_be OTHER_DRUG ,_af amitriptyline_af ,_af mirtazapine_af increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
91,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",citalopram,amitriptyline,No interaction,"Warfarin_bf users_bf initiated_bf DRUG ,_be fluoxetine_be ,_be paroxetine_be ,_be OTHER_DRUG ,_af mirtazapine_af increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
92,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",citalopram,mirtazapine,No interaction,"Warfarin_bf users_bf initiated_bf DRUG ,_be fluoxetine_be ,_be paroxetine_be ,_be amitriptyline_be ,_be OTHER_DRUG increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
93,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",fluoxetine,paroxetine,No interaction,"Warfarin_bf users_bf initiated_bf citalopram_bf ,_bf DRUG ,_be OTHER_DRUG ,_af amitriptyline_af ,_af mirtazapine_af increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
94,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",fluoxetine,amitriptyline,No interaction,"Warfarin_bf users_bf initiated_bf citalopram_bf ,_bf DRUG ,_be paroxetine_be ,_be OTHER_DRUG ,_af mirtazapine_af increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
95,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",fluoxetine,mirtazapine,No interaction,"Warfarin_bf users_bf initiated_bf citalopram_bf ,_bf DRUG ,_be paroxetine_be ,_be amitriptyline_be ,_be OTHER_DRUG increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
96,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",paroxetine,amitriptyline,No interaction,"Warfarin_bf users_bf initiated_bf citalopram_bf ,_bf fluoxetine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af mirtazapine_af increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
97,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",paroxetine,mirtazapine,No interaction,"Warfarin_bf users_bf initiated_bf citalopram_bf ,_bf fluoxetine_bf ,_bf DRUG ,_be amitriptyline_be ,_be OTHER_DRUG increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
98,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",amitriptyline,mirtazapine,No interaction,"Warfarin_bf users_bf initiated_bf citalopram_bf ,_bf fluoxetine_bf ,_bf paroxetine_bf ,_bf DRUG ,_be OTHER_DRUG increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
99,"The incubations were performed in the absence and presence of the non-specific CYP inhibitor, 1-aminobenzotriazole (ABT) and isoform-specific inhibitors. ",1-aminobenzotriazole,ABT,No interaction,"The_bf incubations_bf performed_bf absence_bf presence_bf non-specific_bf CYP_bf inhibitor_bf ,_bf DRUG (ABT)_be isoform-specific_be inhibitors_be ._be"
101,"Of the isoform-specific CYP inhibitors tested for an effect on the precocene I metabolite profile, only tranylcypromine was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1. ",precocene I,tranylcypromine,No interaction,"Of_bf isoform-specific_bf CYP_bf inhibitors_bf tested_bf effect_bf precocene_bf I_bf metabolite_bf profile_bf ,_bf OTHER_DRUG noticeably_be effective_be ,_be indicating_be role_be CYPs_be 2A6_be ,_be 2C9_be ,_be 2Cl9_be ,_be 2E1_be ._be"
102,"With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. ",ABT,diethyldithiocarbamate,No interaction,"With_bf respect_bf toxicity_bf ,_bf order_bf CYP_bf inhibitor_bf effectiveness_bf ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole_bf ._bf"
103,"With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. ",ABT,tranylcypromine,No interaction,"With_bf respect_bf toxicity_bf ,_bf order_bf CYP_bf inhibitor_bf effectiveness_bf ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole_bf ._bf"
104,"With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. ",ABT,ketoconazole,No interaction,"With_bf respect_bf toxicity_bf ,_bf order_bf CYP_bf inhibitor_bf effectiveness_bf ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole_bf ._bf"
105,"With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. ",diethyldithiocarbamate,tranylcypromine,No interaction,"With_bf respect_bf toxicity_bf ,_bf order_bf CYP_bf inhibitor_bf effectiveness_bf ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole_bf ._bf"
106,"With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. ",diethyldithiocarbamate,ketoconazole,No interaction,"With_bf respect_bf toxicity_bf ,_bf order_bf CYP_bf inhibitor_bf effectiveness_bf ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole_bf ._bf"
107,"With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. ",tranylcypromine,ketoconazole,No interaction,"With_bf respect_bf toxicity_bf ,_bf order_bf CYP_bf inhibitor_bf effectiveness_bf ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole_bf ._bf"
108,"Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ",Furafylline,sulfaphenazole,No interaction,"DRUG OTHER_DRUG effect_af ,_af quinidine_af appeared_af augment_af precocene_af I_af toxicity_af ._af"
109,"Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ",Furafylline,quinidine,No interaction,"DRUG sulfaphenazole_be effect_be ,_be OTHER_DRUG appeared_af augment_af precocene_af I_af toxicity_af ._af"
110,"Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ",Furafylline,precocene I,No interaction,"DRUG sulfaphenazole_be effect_be ,_be quinidine_be appeared_be augment_be precocene_be I_be toxicity_be ._be"
111,"Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ",sulfaphenazole,quinidine,No interaction,"Furafylline_bf DRUG effect_be ,_be OTHER_DRUG appeared_af augment_af precocene_af I_af toxicity_af ._af"
112,"Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ",sulfaphenazole,precocene I,No interaction,"Furafylline_bf DRUG effect_be ,_be quinidine_be appeared_be augment_be precocene_be I_be toxicity_be ._be"
114,These results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of precocene I and therefore may not be an appropriate model for precocene I metabolism. ,precocene I,precocene I,No interaction,These_bf results_bf suggest_bf rat_bf liver_bf slices_bf reproduce_bf reported_bf vivo_bf biotransformation_bf precocene_bf I_bf therefore_bf may_bf appropriate_bf model_bf precocene_bf I_bf metabolism_bf ._bf
115,To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of adeno-associated virus-2 (AAV2).,adeno-associated virus-2,AAV2,No interaction,To_bf determine_bf whether_bf co-injection_bf extracellular_bf matrix_bf degrading_bf enzymes_bf improves_bf retinal_bf transduction_bf following_bf intravitreal_bf delivery_bf adeno-associated_bf virus-2_bf (AAV2)_bf ._bf
116,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",AAV2,collagenase,No interaction,"DRUG containing_be cDNA_be encoding_be enhanced_be green_be fluorescent_be protein_be (GFP)_be ,_be control_be chicken_be -actin_be promoter_be ,_be delivered_be intravitreal_be injection_be adult_be mice_be conjunction_be enzymes_be including_be OTHER_DRUG ,_af hyaluronan_af lyase_af ,_af heparinase_af III_af ,_af chondroitin_af ABC_af lyase_af ._af"
117,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",AAV2,hyaluronan lyase,No interaction,"DRUG containing_be cDNA_be encoding_be enhanced_be green_be fluorescent_be protein_be (GFP)_be ,_be control_be chicken_be -actin_be promoter_be ,_be delivered_be intravitreal_be injection_be adult_be mice_be conjunction_be enzymes_be including_be collagenase_be ,_be hyaluronan_be lyase_be ,_be heparinase_be III_be ,_be chondroitin_be ABC_be lyase_be ._be"
118,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",AAV2,heparinase III,No interaction,"DRUG containing_be cDNA_be encoding_be enhanced_be green_be fluorescent_be protein_be (GFP)_be ,_be control_be chicken_be -actin_be promoter_be ,_be delivered_be intravitreal_be injection_be adult_be mice_be conjunction_be enzymes_be including_be collagenase_be ,_be hyaluronan_be lyase_be ,_be heparinase_be III_be ,_be chondroitin_be ABC_be lyase_be ._be"
119,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",AAV2,chondroitin ABC lyase,No interaction,"DRUG containing_be cDNA_be encoding_be enhanced_be green_be fluorescent_be protein_be (GFP)_be ,_be control_be chicken_be -actin_be promoter_be ,_be delivered_be intravitreal_be injection_be adult_be mice_be conjunction_be enzymes_be including_be collagenase_be ,_be hyaluronan_be lyase_be ,_be heparinase_be III_be ,_be chondroitin_be ABC_be lyase_be ._be"
120,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",collagenase,hyaluronan lyase,No interaction,"AAV2_bf containing_bf cDNA_bf encoding_bf enhanced_bf green_bf fluorescent_bf protein_bf (GFP)_bf ,_bf control_bf chicken_bf -actin_bf promoter_bf ,_bf delivered_bf intravitreal_bf injection_bf adult_bf mice_bf conjunction_bf enzymes_bf including_bf DRUG ,_be hyaluronan_be lyase_be ,_be heparinase_be III_be ,_be chondroitin_be ABC_be lyase_be ._be"
121,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",collagenase,heparinase III,No interaction,"AAV2_bf containing_bf cDNA_bf encoding_bf enhanced_bf green_bf fluorescent_bf protein_bf (GFP)_bf ,_bf control_bf chicken_bf -actin_bf promoter_bf ,_bf delivered_bf intravitreal_bf injection_bf adult_bf mice_bf conjunction_bf enzymes_bf including_bf DRUG ,_be hyaluronan_be lyase_be ,_be heparinase_be III_be ,_be chondroitin_be ABC_be lyase_be ._be"
122,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",collagenase,chondroitin ABC lyase,No interaction,"AAV2_bf containing_bf cDNA_bf encoding_bf enhanced_bf green_bf fluorescent_bf protein_bf (GFP)_bf ,_bf control_bf chicken_bf -actin_bf promoter_bf ,_bf delivered_bf intravitreal_bf injection_bf adult_bf mice_bf conjunction_bf enzymes_bf including_bf DRUG ,_be hyaluronan_be lyase_be ,_be heparinase_be III_be ,_be chondroitin_be ABC_be lyase_be ._be"
123,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",hyaluronan lyase,heparinase III,No interaction,"AAV2_bf containing_bf cDNA_bf encoding_bf enhanced_bf green_bf fluorescent_bf protein_bf (GFP)_bf ,_bf control_bf chicken_bf -actin_bf promoter_bf ,_bf delivered_bf intravitreal_bf injection_bf adult_bf mice_bf conjunction_bf enzymes_bf including_bf collagenase_bf ,_bf hyaluronan_bf lyase_bf ,_bf heparinase_bf III_bf ,_bf chondroitin_bf ABC_bf lyase_bf ._bf"
124,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",hyaluronan lyase,chondroitin ABC lyase,No interaction,"AAV2_bf containing_bf cDNA_bf encoding_bf enhanced_bf green_bf fluorescent_bf protein_bf (GFP)_bf ,_bf control_bf chicken_bf -actin_bf promoter_bf ,_bf delivered_bf intravitreal_bf injection_bf adult_bf mice_bf conjunction_bf enzymes_bf including_bf collagenase_bf ,_bf hyaluronan_bf lyase_bf ,_bf heparinase_bf III_bf ,_bf chondroitin_bf ABC_bf lyase_bf ._bf"
125,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",heparinase III,chondroitin ABC lyase,No interaction,"AAV2_bf containing_bf cDNA_bf encoding_bf enhanced_bf green_bf fluorescent_bf protein_bf (GFP)_bf ,_bf control_bf chicken_bf -actin_bf promoter_bf ,_bf delivered_bf intravitreal_bf injection_bf adult_bf mice_bf conjunction_bf enzymes_bf including_bf collagenase_bf ,_bf hyaluronan_bf lyase_bf ,_bf heparinase_bf III_bf ,_bf chondroitin_bf ABC_bf lyase_bf ._bf"
126,The addition of heparinase III or chondroitin ABC lyase greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina. ,heparinase III,chondroitin ABC lyase,No interaction,The_bf addition_bf heparinase_bf III_bf chondroitin_bf ABC_bf lyase_bf greatly_bf enhanced_bf transduction_bf retinal_bf ganglion_bf cell_bf layer_bf increased_bf depth_bf transduction_bf outer_bf retina_bf ._bf
127,Hyaluronan lyase had a limited effect and collagenase was ineffective. ,Hyaluronan lyase,collagenase,No interaction,Hyaluronan_bf lyase_bf limited_bf effect_bf OTHER_DRUG ineffective_be ._be
128,Electroretinograms survived with higher concentrations of heparinase III and chondroitin ABC lyase than were required for optimal retinal transduction. ,heparinase III,chondroitin ABC lyase,No interaction,Electroretinograms_bf survived_bf higher_bf concentrations_bf heparinase_bf III_bf chondroitin_bf ABC_bf lyase_bf required_bf optimal_bf retinal_bf transduction_bf ._bf
131,AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. ,heparinase III,chondroitin ABC lyase,No interaction,AAV2-mediated_bf retinal_bf transduction_bf improved_bf co-injection_bf heparinase_bf III_bf chondroitin_bf ABC_bf lyase_bf ._bf
132,"Prevention of emergence agitation in seven children receiving low-dose ketamine and propofol total intravenous anesthesia.
",ketamine,propofol,No interaction,Prevention_bf emergence_bf agitation_bf seven_bf children_bf receiving_bf low-dose_bf DRUG OTHER_DRUG total_af intravenous_af anesthesia_af ._af
133,We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose ketamine in conjunction with propofol for total intravenous anesthesia (TIVA) repeatedly for radiation therapy. ,ketamine,propofol,No interaction,We_bf retrospectively_bf reviewed_bf records_bf 7_bf pediatric_bf oncology_bf patients_bf received_bf low-dose_bf DRUG conjunction_be OTHER_DRUG total_af intravenous_af anesthesia_af (TIVA)_af repeatedly_af radiation_af therapy_af ._af
134,EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. ,propofol,ketamine,No interaction,EA_bf signs_bf observed_bf 7_bf patients_bf association_bf DRUG TIVA_be recur_be 123_be subsequent_be anesthetics_be sessions_be low-dose_be OTHER_DRUG added_af DRUG ._af
135,EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. ,propofol,propofol,No interaction,EA_bf signs_bf observed_bf 7_bf patients_bf association_bf DRUG TIVA_be recur_be 123_be subsequent_be anesthetics_be sessions_be low-dose_be ketamine_be added_be DRUG ._af
136,EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. ,ketamine,propofol,No interaction,EA_bf signs_bf observed_bf 7_bf patients_bf association_bf OTHER_DRUG TIVA_be recur_be 123_be subsequent_be anesthetics_be sessions_be low-dose_be DRUG added_af OTHER_DRUG ._af
138,"Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.",ketamine,propofol,No interaction,"Based_bf experience_bf ,_bf suggest_bf low-dose_bf DRUG added_be OTHER_DRUG may_af associated_af prevention_af EA_af children_af history_af EA_af OTHER_DRUG TIVA_af ._af"
139,"Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.",propofol,propofol,No interaction,"Based_bf experience_bf ,_bf suggest_bf low-dose_bf ketamine_bf added_bf DRUG may_be associated_be prevention_be EA_be children_be history_be EA_be DRUG TIVA_af ._af"
140,"Tamoxifen, an estrogen antagonist, is the standard hormone treatment for breast cancer. ",Tamoxifen,estrogen antagonist,No interaction,"DRUG ,_be estrogen_be antagonist_be ,_be standard_be hormone_be treatment_be breast_be cancer_be ._be"
141,Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. ,Paroxetine,fluoxetine,No interaction,DRUG OTHER_DRUG reduce_af plasma_af concentration_af endoxifen_af 50%_af ._af
147,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ",SSRI antidepressants,paroxetine,No interaction,"It_bf better_bf avoid_bf prescribing_bf isoenzyme_bf CYP_bf 2D6_bf inhibitors_bf women_bf treated_bf tamoxifen_bf breast_bf cancer_bf ,_bf especially_bf SSRI_bf antidepressants_bf OTHER_DRUG fluoxetine_be ._be"
148,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ",SSRI antidepressants,fluoxetine,No interaction,"It_bf better_bf avoid_bf prescribing_bf isoenzyme_bf CYP_bf 2D6_bf inhibitors_bf women_bf treated_bf tamoxifen_bf breast_bf cancer_bf ,_bf especially_bf SSRI_bf antidepressants_bf paroxetine_bf OTHER_DRUG ._be"
149,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ",paroxetine,fluoxetine,No interaction,"It_bf better_bf avoid_bf prescribing_bf isoenzyme_bf CYP_bf 2D6_bf inhibitors_bf women_bf treated_bf tamoxifen_bf breast_bf cancer_bf ,_bf especially_bf SSRI_bf antidepressants_bf DRUG OTHER_DRUG ._af"
150,"Depression does not always require antidepressant drug therapy, and antidepressants have no proven preventive impact on hot flushes linked to the menopause. ",antidepressant drug,antidepressants,No interaction,"Depression_bf always_bf require_bf antidepressant_bf drug_bf therapy_bf ,_bf OTHER_DRUG proven_be preventive_be impact_be hot_be flushes_be linked_be menopause_be ._be"
152,"If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.",antidepressant,anastrozole,No interaction,"If_bf certain_bf cases_bf ,_bf DRUG considered_be necessary_be ,_be may_be advisable_be replace_be tamoxifen_be OTHER_DRUG ._af"
153,"If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.",tamoxifen,anastrozole,No interaction,"If_bf certain_bf cases_bf ,_bf antidepressant_bf considered_bf necessary_bf ,_bf may_bf advisable_bf replace_bf DRUG OTHER_DRUG ._af"
154,"Amphetamine locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with quinpirole.
",Amphetamine,quinpirole,No interaction,DRUG locomotor_be sensitization_be conditioned_be place_be preference_be adolescent_be male_be female_be rats_be neonatally_be treated_be OTHER_DRUG ._af
155,The objective was to analyze the effects of neonatal quinpirole treatment on effects of amphetamine in adolescent rats using locomotor sensitization and conditioned place preference procedures. ,quinpirole,amphetamine,No interaction,The_bf objective_bf analyze_bf effects_bf neonatal_bf DRUG treatment_be effects_be OTHER_DRUG adolescent_af rats_af using_af locomotor_af sensitization_af conditioned_af place_af preference_af procedures_af ._af
157,"In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ",quinpirole,quinpirole,No interaction,"In_bf female_bf rats_bf ,_bf neonatal_bf DRUG treatment_be enhanced_be amphetamine_be locomotor_be sensitization_be compared_be quinpirole-free_be controls_be sensitized_be amphetamine_be ._be"
158,"In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ",quinpirole,amphetamine,No interaction,"In_bf female_bf rats_bf ,_bf neonatal_bf DRUG treatment_be enhanced_be OTHER_DRUG locomotor_af sensitization_af compared_af quinpirole-free_af controls_af sensitized_af OTHER_DRUG ._af"
159,"In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ",amphetamine,quinpirole,No interaction,"In_bf female_bf rats_bf ,_bf neonatal_bf OTHER_DRUG treatment_be enhanced_be DRUG locomotor_af sensitization_af compared_af quinpirole-free_af controls_af sensitized_af DRUG ._af"
160,"In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ",amphetamine,amphetamine,No interaction,"In_bf female_bf rats_bf ,_bf neonatal_bf quinpirole_bf treatment_bf enhanced_bf DRUG locomotor_be sensitization_be compared_be quinpirole-free_be controls_be sensitized_be DRUG ._af"
161,"In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ",quinpirole,amphetamine,No interaction,"In_bf female_bf rats_bf ,_bf neonatal_bf DRUG treatment_be enhanced_be OTHER_DRUG locomotor_af sensitization_af compared_af quinpirole-free_af controls_af sensitized_af OTHER_DRUG ._af"
162,"Male rats demonstrated sensitization to amphetamine, although this was muted compared with female rats, and were unaffected by neonatal quinpirole. ",amphetamine,quinpirole,No interaction,"Male_bf rats_bf demonstrated_bf sensitization_bf DRUG ,_be although_be muted_be compared_be female_be rats_be ,_be unaffected_be neonatal_be OTHER_DRUG ._af"
163,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",quinpirole,amphetamine,No interaction,"Rats_bf treated_bf neonatal_bf DRUG enhanced_be time_be spent_be amphetamine-paired_be context_be compared_be quinpirole-free_be controls_be conditioned_be OTHER_DRUG ,_af female_af controls_af conditioned_af OTHER_DRUG spent_af time_af drug-paired_af context_af compared_af saline-treated_af controls_af ._af"
164,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",quinpirole,quinpirole,No interaction,"Rats_bf treated_bf neonatal_bf DRUG enhanced_be time_be spent_be amphetamine-paired_be context_be compared_be quinpirole-free_be controls_be conditioned_be amphetamine_be ,_be female_be controls_be conditioned_be amphetamine_be spent_be time_be drug-paired_be context_be compared_be saline-treated_be controls_be ._be"
165,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",quinpirole,amphetamine,No interaction,"Rats_bf treated_bf neonatal_bf DRUG enhanced_be time_be spent_be amphetamine-paired_be context_be compared_be quinpirole-free_be controls_be conditioned_be OTHER_DRUG ,_af female_af controls_af conditioned_af OTHER_DRUG spent_af time_af drug-paired_af context_af compared_af saline-treated_af controls_af ._af"
166,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",quinpirole,amphetamine,No interaction,"Rats_bf treated_bf neonatal_bf DRUG enhanced_be time_be spent_be amphetamine-paired_be context_be compared_be quinpirole-free_be controls_be conditioned_be OTHER_DRUG ,_af female_af controls_af conditioned_af OTHER_DRUG spent_af time_af drug-paired_af context_af compared_af saline-treated_af controls_af ._af"
167,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",amphetamine,quinpirole,No interaction,"Rats_bf treated_bf neonatal_bf OTHER_DRUG enhanced_be time_be spent_be amphetamine-paired_be context_be compared_be quinpirole-free_be controls_be conditioned_be DRUG ,_af female_af controls_af conditioned_af DRUG spent_af time_af drug-paired_af context_af compared_af saline-treated_af controls_af ._af"
168,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",amphetamine,amphetamine,No interaction,"Rats_bf treated_bf neonatal_bf quinpirole_bf enhanced_bf time_bf spent_bf amphetamine-paired_bf context_bf compared_bf quinpirole-free_bf controls_bf conditioned_bf DRUG ,_be female_be controls_be conditioned_be DRUG spent_af time_af drug-paired_af context_af compared_af saline-treated_af controls_af ._af"
169,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",amphetamine,amphetamine,No interaction,"Rats_bf treated_bf neonatal_bf quinpirole_bf enhanced_bf time_bf spent_bf amphetamine-paired_bf context_bf compared_bf quinpirole-free_bf controls_bf conditioned_bf DRUG ,_be female_be controls_be conditioned_be DRUG spent_af time_af drug-paired_af context_af compared_af saline-treated_af controls_af ._af"
170,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",quinpirole,amphetamine,No interaction,"Rats_bf treated_bf neonatal_bf DRUG enhanced_be time_be spent_be amphetamine-paired_be context_be compared_be quinpirole-free_be controls_be conditioned_be OTHER_DRUG ,_af female_af controls_af conditioned_af OTHER_DRUG spent_af time_af drug-paired_af context_af compared_af saline-treated_af controls_af ._af"
171,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",quinpirole,amphetamine,No interaction,"Rats_bf treated_bf neonatal_bf DRUG enhanced_be time_be spent_be amphetamine-paired_be context_be compared_be quinpirole-free_be controls_be conditioned_be OTHER_DRUG ,_af female_af controls_af conditioned_af OTHER_DRUG spent_af time_af drug-paired_af context_af compared_af saline-treated_af controls_af ._af"
172,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",amphetamine,amphetamine,No interaction,"Rats_bf treated_bf neonatal_bf quinpirole_bf enhanced_bf time_bf spent_bf amphetamine-paired_bf context_bf compared_bf quinpirole-free_bf controls_bf conditioned_bf DRUG ,_be female_be controls_be conditioned_be DRUG spent_af time_af drug-paired_af context_af compared_af saline-treated_af controls_af ._af"
173,"In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.
",cyclosporine,tacrolimus,No interaction,In_bf vivo_bf CYP3A_bf activity_bf significantly_bf lower_bf cyclosporine-treated_bf compared_bf tacrolimus-treated_bf renal_bf allograft_bf recipients_bf ._bf
174,In vitro studies have identified cyclosporine and tacrolimus as CYP3A inhibitors. ,cyclosporine,tacrolimus,No interaction,In_bf vitro_bf studies_bf identified_bf DRUG OTHER_DRUG CYP3A_af inhibitors_af ._af
176,"Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). ",midazolam,tacrolimus,No interaction,"Systemic_bf apparent_bf oral_bf DRUG clearance_be 24%_be (269_be 73_be vs_be ._be 354_be 102_be ml/min_be ,_be P_be =_be 0_be ._be 022)_be 31%_be (479_be 190_be vs_be ._be 688_be 265_be ml/min_be ,_be P_be =_be 0_be ._be 013)_be ,_be respectively_be ,_be lower_be cyclosporine-treated_be patients_be (n_be =_be 20)_be matched_be tacrolimus-treated_be patients_be (n_be =_be 20)_be ._be"
177,"Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). ",cyclosporine,tacrolimus,No interaction,"Systemic_bf apparent_bf oral_bf midazolam_bf clearance_bf 24%_bf (269_bf 73_bf vs_bf ._bf 354_bf 102_bf ml/min_bf ,_bf P_bf =_bf 0_bf ._bf 022)_bf 31%_bf (479_bf 190_bf vs_bf ._bf 688_bf 265_bf ml/min_bf ,_bf P_bf =_bf 0_bf ._bf 013)_bf ,_bf respectively_bf ,_bf lower_bf cyclosporine-treated_bf patients_bf (n_bf =_bf 20)_bf matched_bf tacrolimus-treated_bf patients_bf (n_bf =_bf 20)_bf ._bf"
178,The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). ,midazolam,tacrolimus,No interaction,The_bf latter_bf displayed_bf DRUG clearances_be similar_be two_be larger_be cohorts_be nonmatched_be tacrolimus-treated_be patients_be (n_be =_be 58_be n_be =_be 80)_be receiving_be calcineurin_be inhibitor-free_be regimen_be (n_be =_be 6)_be ._be
179,The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). ,midazolam,calcineurin inhibitor,No interaction,The_bf latter_bf displayed_bf DRUG clearances_be similar_be two_be larger_be cohorts_be nonmatched_be tacrolimus-treated_be patients_be (n_be =_be 58_be n_be =_be 80)_be receiving_be calcineurin_be inhibitor-free_be regimen_be (n_be =_be 6)_be ._be
180,The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). ,tacrolimus,calcineurin inhibitor,No interaction,The_bf latter_bf displayed_bf midazolam_bf clearances_bf similar_bf two_bf larger_bf cohorts_bf nonmatched_bf tacrolimus-treated_bf patients_bf (n_bf =_bf 58_bf n_bf =_bf 80)_bf receiving_bf calcineurin_bf inhibitor-free_bf regimen_bf (n_bf =_bf 6)_bf ._bf
181,"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. ",cyclosporine,tacrolimus,No interaction,"This_bf implies_bf vivo_bf hepatic_bf first-pass_bf CYP3A_bf activities_bf significantly_bf lower_bf patients_bf receiving_bf DRUG receiving_be OTHER_DRUG ,_af indicating_af ,_af doses_af generally_af used_af clinical_af practice_af ,_af DRUG stronger_af two_af respect_af CYP3A_af inhibition_af ._af"
182,"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. ",cyclosporine,cyclosporine,No interaction,"This_bf implies_bf vivo_bf hepatic_bf first-pass_bf CYP3A_bf activities_bf significantly_bf lower_bf patients_bf receiving_bf DRUG receiving_be tacrolimus_be ,_be indicating_be ,_be doses_be generally_be used_be clinical_be practice_be ,_be DRUG stronger_af two_af respect_af CYP3A_af inhibition_af ._af"
183,"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. ",tacrolimus,cyclosporine,No interaction,"This_bf implies_bf vivo_bf hepatic_bf first-pass_bf CYP3A_bf activities_bf significantly_bf lower_bf patients_bf receiving_bf OTHER_DRUG receiving_be DRUG ,_af indicating_af ,_af doses_af generally_af used_af clinical_af practice_af ,_af OTHER_DRUG stronger_af two_af respect_af CYP3A_af inhibition_af ._af"
184,"Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease.
",cinacalcet,darbepoetin,No interaction,Improved_bf parathyroid_bf hormone_bf control_bf DRUG associated_be reduction_be OTHER_DRUG requirement_af patients_af end-stage_af renal_af disease_af ._af
185,"Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to erythropoietin (EPO) resistance. ",erythropoietin,EPO,No interaction,"Uncontrolled_bf hy-per-parathyroidism_bf causes_bf bone_bf marrow_bf fibrosis_bf ,_bf leading_bf DRUG (EPO)_be resistance_be ._be"
186,"Medical treatment with cinacalcet is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on darbepoetin dosing is unknown. ",cinacalcet,darbepoetin,No interaction,"Medical_bf treatment_bf DRUG effective_be reducing_be plasma_be parathyroid_be hormone_be (PTH)_be levels_be ,_be effect_be OTHER_DRUG dosing_af unknown_af ._af"
187,The primary objective of the study was to ascertain the difference in darbepoetin responsiveness before and after 12 months of cinacalcet therapy. ,darbepoetin,cinacalcet,No interaction,The_bf primary_bf objective_bf study_bf ascertain_bf difference_bf DRUG responsiveness_be 12_be months_be OTHER_DRUG therapy_af ._af
190,This study investigates the ability of cyclooxygenase-2 inhibitors to sensitize cells from different origins to several chemotherapeutic agents. ,cyclooxygenase-2 inhibitors,chemotherapeutic agents,No interaction,This_bf study_bf investigates_bf ability_bf cyclooxygenase-2_bf inhibitors_bf sensitize_bf cells_bf different_bf origins_bf several_bf chemotherapeutic_bf agents_bf ._bf
191,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",5-FU,cisplatin,No interaction,"The_bf sensitivity_bf ,_bf cell_bf cycle_bf ,_bf apoptosis_bf DNA_bf damage_bf five_bf different_bf cancer_bf cell_bf lines_bf (HeLa_bf ,_bf HCT116_bf ,_bf HepG2_bf ,_bf MCF7_bf U251)_bf DRUG ,_be OTHER_DRUG ,_af doxorubicin_af etoposide_af celecoxib_af following_af different_af incubation_af schedules_af analyzed_af ._af"
192,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",5-FU,doxorubicin,No interaction,"The_bf sensitivity_bf ,_bf cell_bf cycle_bf ,_bf apoptosis_bf DNA_bf damage_bf five_bf different_bf cancer_bf cell_bf lines_bf (HeLa_bf ,_bf HCT116_bf ,_bf HepG2_bf ,_bf MCF7_bf U251)_bf DRUG ,_be cisplatin_be ,_be OTHER_DRUG etoposide_af celecoxib_af following_af different_af incubation_af schedules_af analyzed_af ._af"
193,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",5-FU,etoposide,No interaction,"The_bf sensitivity_bf ,_bf cell_bf cycle_bf ,_bf apoptosis_bf DNA_bf damage_bf five_bf different_bf cancer_bf cell_bf lines_bf (HeLa_bf ,_bf HCT116_bf ,_bf HepG2_bf ,_bf MCF7_bf U251)_bf DRUG ,_be cisplatin_be ,_be doxorubicin_be OTHER_DRUG celecoxib_af following_af different_af incubation_af schedules_af analyzed_af ._af"
194,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",5-FU,celecoxib,No interaction,"The_bf sensitivity_bf ,_bf cell_bf cycle_bf ,_bf apoptosis_bf DNA_bf damage_bf five_bf different_bf cancer_bf cell_bf lines_bf (HeLa_bf ,_bf HCT116_bf ,_bf HepG2_bf ,_bf MCF7_bf U251)_bf DRUG ,_be cisplatin_be ,_be doxorubicin_be etoposide_be OTHER_DRUG following_af different_af incubation_af schedules_af analyzed_af ._af"
195,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",cisplatin,doxorubicin,No interaction,"The_bf sensitivity_bf ,_bf cell_bf cycle_bf ,_bf apoptosis_bf DNA_bf damage_bf five_bf different_bf cancer_bf cell_bf lines_bf (HeLa_bf ,_bf HCT116_bf ,_bf HepG2_bf ,_bf MCF7_bf U251)_bf 5-FU_bf ,_bf DRUG ,_be OTHER_DRUG etoposide_af celecoxib_af following_af different_af incubation_af schedules_af analyzed_af ._af"
196,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",cisplatin,etoposide,No interaction,"The_bf sensitivity_bf ,_bf cell_bf cycle_bf ,_bf apoptosis_bf DNA_bf damage_bf five_bf different_bf cancer_bf cell_bf lines_bf (HeLa_bf ,_bf HCT116_bf ,_bf HepG2_bf ,_bf MCF7_bf U251)_bf 5-FU_bf ,_bf DRUG ,_be doxorubicin_be OTHER_DRUG celecoxib_af following_af different_af incubation_af schedules_af analyzed_af ._af"
197,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",cisplatin,celecoxib,No interaction,"The_bf sensitivity_bf ,_bf cell_bf cycle_bf ,_bf apoptosis_bf DNA_bf damage_bf five_bf different_bf cancer_bf cell_bf lines_bf (HeLa_bf ,_bf HCT116_bf ,_bf HepG2_bf ,_bf MCF7_bf U251)_bf 5-FU_bf ,_bf DRUG ,_be doxorubicin_be etoposide_be OTHER_DRUG following_af different_af incubation_af schedules_af analyzed_af ._af"
198,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",doxorubicin,etoposide,No interaction,"The_bf sensitivity_bf ,_bf cell_bf cycle_bf ,_bf apoptosis_bf DNA_bf damage_bf five_bf different_bf cancer_bf cell_bf lines_bf (HeLa_bf ,_bf HCT116_bf ,_bf HepG2_bf ,_bf MCF7_bf U251)_bf 5-FU_bf ,_bf cisplatin_bf ,_bf DRUG OTHER_DRUG celecoxib_af following_af different_af incubation_af schedules_af analyzed_af ._af"
199,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",doxorubicin,celecoxib,No interaction,"The_bf sensitivity_bf ,_bf cell_bf cycle_bf ,_bf apoptosis_bf DNA_bf damage_bf five_bf different_bf cancer_bf cell_bf lines_bf (HeLa_bf ,_bf HCT116_bf ,_bf HepG2_bf ,_bf MCF7_bf U251)_bf 5-FU_bf ,_bf cisplatin_bf ,_bf DRUG etoposide_be OTHER_DRUG following_af different_af incubation_af schedules_af analyzed_af ._af"
200,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",etoposide,celecoxib,No interaction,"The_bf sensitivity_bf ,_bf cell_bf cycle_bf ,_bf apoptosis_bf DNA_bf damage_bf five_bf different_bf cancer_bf cell_bf lines_bf (HeLa_bf ,_bf HCT116_bf ,_bf HepG2_bf ,_bf MCF7_bf U251)_bf 5-FU_bf ,_bf cisplatin_bf ,_bf doxorubicin_bf DRUG OTHER_DRUG following_af different_af incubation_af schedules_af analyzed_af ._af"
201,We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. ,celecoxib,celecoxib,No interaction,We_bf found_bf antagonism_bf DRUG four_be drugs_be breast_be cancer_be cells_be MCF7_be following_be incubation_be schedules_be DRUG doxorubicin_af cell_af lines_af except_af two_af combinations_af HCT116_af cells_af ._af
202,We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. ,celecoxib,doxorubicin,No interaction,We_bf found_bf antagonism_bf DRUG four_be drugs_be breast_be cancer_be cells_be MCF7_be following_be incubation_be schedules_be DRUG OTHER_DRUG cell_af lines_af except_af two_af combinations_af HCT116_af cells_af ._af
204,"These results, if confirmed in-vivo, indicate that celecoxib is not a suitable chemosensitizer for breast cancer or with doxorubicin for other cancers. ",celecoxib,doxorubicin,No interaction,"These_bf results_bf ,_bf confirmed_bf in-vivo_bf ,_bf indicate_bf DRUG suitable_be chemosensitizer_be breast_be cancer_be OTHER_DRUG cancers_af ._af"
205,"[Interaction between clopidogrel and proton pump inhibitors].
",clopidogrel,proton pump inhibitors,No interaction,[Interaction_bf DRUG proton_be pump_be inhibitors]_be ._be
206,The drug interaction between proton pump inhibitors and clopidogrel has been the subject of much study in recent years. ,proton pump inhibitors,clopidogrel,No interaction,The_bf drug_bf interaction_bf proton_bf pump_bf inhibitors_bf OTHER_DRUG subject_be much_be study_be recent_be years_be ._be
207,Contradictory results regarding the effect of proton pump inhibitors on platelet reactivity and on clinical outcome in clopidogrel-treated patients have been reported in literature. ,proton pump inhibitors,clopidogrel,No interaction,Contradictory_bf results_bf regarding_bf effect_bf proton_bf pump_bf inhibitors_bf platelet_bf reactivity_bf clinical_bf outcome_bf clopidogrel-treated_bf patients_bf reported_bf literature_bf ._bf
209,"Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. ",omeprazole,omeprazole,No interaction,"Concomitant_bf use_bf DRUG clopidogrel_be found_be decrease_be exposure_be (AUC)_be clopidogrel's_be active_be metabolite_be 50%_be sharply_be increase_be platelet_be reactivity_be ,_be result_be inhibition_be DRUG CYP2C19_af ,_af cytochrome_af P450_af (CYP)_af enzyme_af ._af"
210,"Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. ",clopidogrel,omeprazole,No interaction,"Concomitant_bf use_bf OTHER_DRUG DRUG found_af decrease_af exposure_af (AUC)_af clopidogrel's_af active_af metabolite_af 50%_af sharply_af increase_af platelet_af reactivity_af ,_af result_af inhibition_af OTHER_DRUG CYP2C19_af ,_af cytochrome_af P450_af (CYP)_af enzyme_af ._af"
212,The influence of the other proton pump inhibitors when used simultaneously with clopidogrel has not yet been investigated in adequately randomized studies. ,proton pump inhibitors,clopidogrel,No interaction,The_bf influence_bf proton_bf pump_bf inhibitors_bf used_bf simultaneously_bf OTHER_DRUG yet_be investigated_be adequately_be randomized_be studies_be ._be
215,Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. ,omeprazole,esomeprazole,No interaction,Regulatory_bf agencies_bf state_bf combination_bf clopidogrel_bf CYP2C19_bf inhibitors_bf DRUG OTHER_DRUG avoided_af ._af
216,"To date, there is no conclusive evidence of a clinically-relevant interaction between any of the proton pump inhibitors and clopidogrel.",proton pump inhibitors,clopidogrel,No interaction,"To_bf date_bf ,_bf conclusive_bf evidence_bf clinically-relevant_bf interaction_bf proton_bf pump_bf inhibitors_bf OTHER_DRUG ._be"
217,"In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.
",minocycline,fosfomycin,No interaction,In_bf vitro_bf activity_bf DRUG combined_be OTHER_DRUG clinical_af isolates_af methicillin-resistant_af Staphylococcus_af aureus_af ._af
218,"In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.
",minocycline,methicillin,No interaction,In_bf vitro_bf activity_bf DRUG combined_be fosfomycin_be clinical_be isolates_be methicillin-resistant_be Staphylococcus_be aureus_be ._be
219,"In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.
",fosfomycin,methicillin,No interaction,In_bf vitro_bf activity_bf minocycline_bf combined_bf DRUG clinical_be isolates_be methicillin-resistant_be Staphylococcus_be aureus_be ._be
220,This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA). ,minocycline,fosfomycin,No interaction,This_bf study_bf aimed_bf evaluate_bf vitro_bf activity_bf DRUG combined_be OTHER_DRUG isolates_af methicillin-resistant_af Staphylococcus_af aureus_af (MRSA)_af ._af
221,This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA). ,minocycline,methicillin,No interaction,This_bf study_bf aimed_bf evaluate_bf vitro_bf activity_bf DRUG combined_be fosfomycin_be isolates_be methicillin-resistant_be Staphylococcus_be aureus_be (MRSA)_be ._be
222,This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA). ,fosfomycin,methicillin,No interaction,This_bf study_bf aimed_bf evaluate_bf vitro_bf activity_bf minocycline_bf combined_bf DRUG isolates_be methicillin-resistant_be Staphylococcus_be aureus_be (MRSA)_be ._be
223,The susceptibility results for minocycline and fosfomycin were interpreted according to the most relevant criteria. ,minocycline,fosfomycin,No interaction,The_bf susceptibility_bf results_bf DRUG OTHER_DRUG interpreted_af according_af relevant_af criteria_af ._af
226,Questioning revealed the child was taking Infacol drops before feeds while on levothyroxine. ,Infacol,levothyroxine,No interaction,Questioning_bf revealed_bf child_bf taking_bf DRUG drops_be feeds_be OTHER_DRUG ._af
227,Drug interaction of thyroxine with simeticone has not been reported previously and is not listed in the British National Formulary for Children. ,thyroxine,simeticone,No interaction,Drug_bf interaction_bf DRUG OTHER_DRUG reported_af previously_af listed_af British_af National_af Formulary_af Children_af ._af
228,Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.,Calcium,nonheme iron,No interaction,DRUG inhibit_be absorption_be 5_be milligrams_be nonheme_be heme_be iron_be doses_be less_be 800_be milligrams_be nonpregnant_be women_be ._be
229,Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.,Calcium,heme iron,No interaction,DRUG inhibit_be absorption_be 5_be milligrams_be nonheme_be heme_be iron_be doses_be less_be 800_be milligrams_be nonpregnant_be women_be ._be
230,Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.,nonheme iron,heme iron,No interaction,Calcium_bf inhibit_bf absorption_bf 5_bf milligrams_bf nonheme_bf heme_bf iron_bf doses_bf less_bf 800_bf milligrams_bf nonpregnant_bf women_bf ._bf
233,Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. ,nonheme iron,heme iron,No interaction,Calcium_bf known_bf component_bf diet_bf may_bf affect_bf absorption_bf nonheme_bf heme_bf iron_bf ._bf
235,"However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. ",calcium,calcium,No interaction,"However_bf ,_bf evidence_bf DRUG effect_be iron_be absorption_be mainly_be comes_be studies_be isolate_be effect_be DRUG dietary_af components_af ,_af detected_af single-meal_af studies_af ._af"
236,"However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. ",iron,calcium,No interaction,"However_bf ,_bf evidence_bf OTHER_DRUG effect_be DRUG absorption_af mainly_af comes_af studies_af isolate_af effect_af OTHER_DRUG dietary_af components_af ,_af detected_af single-meal_af studies_af ._af"
237,Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal. ,calcium,nonheme iron,No interaction,Our_bf objective_bf establish_bf potential_bf effects_bf DRUG absorption_be nonheme_be heme_be iron_be dose_be response_be effect_be absence_be meal_be ._be
238,Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal. ,calcium,heme iron,No interaction,Our_bf objective_bf establish_bf potential_bf effects_bf DRUG absorption_be nonheme_be heme_be iron_be dose_be response_be effect_be absence_be meal_be ._be
239,Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal. ,nonheme iron,heme iron,No interaction,Our_bf objective_bf establish_bf potential_bf effects_bf calcium_bf absorption_bf nonheme_bf heme_bf iron_bf dose_bf response_bf effect_bf absence_bf meal_bf ._bf
240,We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate). ,calcium,nonheme iron,No interaction,We_bf evaluated_bf effects_bf DRUG doses_be 200_be 1500_be mg_be absorption_be 5_be mg_be nonheme_be iron_be (as_be ferrous_be sulfate)_be ._be
241,We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate). ,calcium,ferrous sulfate,No interaction,We_bf evaluated_bf effects_bf DRUG doses_be 200_be 1500_be mg_be absorption_be 5_be mg_be nonheme_be iron_be (as_be ferrous_be sulfate)_be ._be
242,We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate). ,nonheme iron,ferrous sulfate,No interaction,We_bf evaluated_bf effects_bf calcium_bf doses_bf 200_bf 1500_bf mg_bf absorption_bf 5_bf mg_bf nonheme_bf iron_bf (as_bf ferrous_bf sulfate)_bf ._bf
243,We also evaluated the effects of calcium doses between 200 and 800 mg on absorption of 5 mg heme iron [as concentrated RBC (CRBC)]. ,calcium,heme iron,No interaction,We_bf also_bf evaluated_bf effects_bf DRUG doses_be 200_be 800_be mg_be absorption_be 5_be mg_be heme_be iron_be [as_be concentrated_be RBC_be (CRBC)]_be ._be
